

Pier Giuseppe Pelicci, M.D. - Ph.D.

Titoli di Studio

1987	Dottorato di Ricerca in Biologia Molecolare, Università di Perugia.
1987	Specializzazione in Medicina Interna, Università di Perugia, 50/50 e lode.
1981	Laurea in Medicina e Chirurgia, Università di Perugia, 110/110 e lode.

Carriera professionale

2015-oggi	Direttore della Ricerca dell'Istituto Europeo di Oncologia (IEO), Milano.
1996-oggi	Direttore del Dipartimento di Oncologia Sperimentale, IEO, Milano.
2018-oggi	Presidente della "Scuola Superiore Europea di Medicina Molecolare" (SEMM), Milano.
2010-2014	Co-Direttore Scientifico dell'Istituto Europeo di Oncologia (IEO), Milano.
2001-2018	Co-Fondatore e Direttore Scientifico della "Scuola Superiore Europea di Medicina Molecolare" (SEMM), Milano.
2010-2015	Co-Fondatore e Presidente di TTFactor Srl, società di Technology Transfer di IEO e IFOM, Milano
2013-2016	Direttore del Programma di Ematologia Clinica (IEO), Milano.
2005-2012	Co-Fondatore e Presidente del Consorzio Cogentech, la piattaforma di tecnologie genomiche di IEO e IFOM, Milano
1987-1995	Aiuto medico di Ematologia Clinica e Responsabile del laboratorio di biologia molecolare e di diagnostica molecolare dei tumori dell'Istituto di Clinica Medica I dell'Università di Perugia, Perugia.
1983-1986	Ricercatore presso il laboratorio di biologia molecolare della "New York University Medical Center", New York.
1982	Ricercatore presso "Institut National de la Sante et de la Recherche Medicale", Creteil, France.

Posizioni Accademiche

2004-oggi	Professore Ordinario di Patologia Generale, Facoltà di Medicina e Chirurgia, Università degli Studi di Milano, Milano.
2000-2003	Professore Ordinario di Patologia Generale, Facoltà di Medicina e Chirurgia, Università Vita Salute S. Raffaele, Milano.
2000-2002	Visiting Professor, New York Medical College, New York.
1994-2000	Professore Associato di Oncologia Medica, Facoltà di Medicina, Università di Parma, Parma.

Comitati Scientifici

European Research Council (ERC), Bruxelles; MD Anderson Cancer Center, Houston; Cancer Research UK (CRUK), Londra; Biotech Research and Innovation Centre (BRIC), Copenhagen; Cancer Science Institute, Singapore; Netherland Cancer Institute (NKI), Amsterdam; "Giovanni Armenise Harvard Foundation", Boston; World Oncology Forum (WOF), Lugano; International Human Epigenome Consortium (IHEC), Los Angeles; European Academy of Cancer Sciences (EACS), Bruxelles; European Cancer Organisation (ECCO), Bruxelles; Alleanza Contro il Cancro (ACC), Roma; Fondazione "Carlo Erba", Milano; Polo di Innovazione in Genomica, Genetica e Biologia Università di Perugia, Perugia; Fondazione "Grazia Focacci", Milano; Istituto FIRC di Oncologia Molecolare (IFOM), Milano; Southern Europe New Drug Organization (SENDO), Bellinzona; Fondazione "Silvio Tronchetti Provera", Milano; Fondazione "Istituto Europeo di Oncologia-Centro Cardiologico Monzino" (IEO-CCM), Milano; Associazione Italiana Ricerca Contro il Cancro (AIRC), Milano; Fondazione "Umberto Veronesi" (FUV), Milano.

Società Scientifiche

European Molecular Biology Organization (EMBO); American Association for Cancer Research (AACR); American Society of Hematology (ASH); American Society for Biochemistry and Molecular Biology (ASBMB); European Haematology Association (EHA); European Society for Medical Oncology (ESMO); Italian Association of Cell Biology and Differentiation (ABCD).

Editorial Board

Leukemia (Editorial Board); *ecancermedalscience* (Founding Editor); *Frontiers in Molecular and Cellular Oncology* (Associate Editor); *Genes Chromosome and Cancer* (Editorial Board); *Journal of Cellular Physiology* (Associate Editor); *Tumori - A Journal of Experimental and Clinical Oncology* (Advisory Board).

Premi

2012	Premio Città di Firenze, Firenze
2012	Premio Cartagine, Roma
2010	Premio Casentino, Arezzo
2009	Premio Stella di Tabor, Amalfi (SA)
2009	Premio San Valentino d'Oro, Terni
2008	Premio Bontà, Gubbio (PG)
2007	Swiss Bridge Award, Zurigo, Svizzera
2007	Premio Bandiera, Gubbio (PG)
2006	Premio Angelo dell'Anno by SolidArte ONLUS, Milano
2001	Premio Ospedale San Raffaele, Milano
2000	Associazione Nuova Spoleto Award for Medical Research, Spoleto (PG)
2000	Ercole Pisello Award for Excellence in Medicine, Deruta (PG)
1998	American-Italian Foundation for Cancer Research Award for Excellence in Medicine, New York, USA.
1998	Premio Guido Venosta (Italian Cancer Research Foundation - FIRC), Milano
1996	Premio Cassa di Risparmio di Asti Foundation, Asti
1996	Premio Chiara d'Onofrio Foundation, Pomezia (RM)
1992	Cecilia Cioffrese Award for Cancer Research (Carlo Erba Foundation), Milano
1989	Fellowship from the Anna Villa Rusconi Foundation, Varese
1988	Favretto Foundation Award for oncologists, Torino
1987	Fellowship from the Associazione Umbra Lotta Leucemie e Linfomi, Perugia
1986	Senior Fellowship for AIDS research from the Kaplan Cancer Center, New York University, New York, USA.
1985	Fellowship from the American-Italian Foundation for Cancer Research, New York, USA.
1984	Fellowship from the "Ministero Italiano della Pubblica Istruzione per il perfezionamento presso istituzioni estere di livello universitario", Roma
1983	Fellowship from Fidia spa, Abano Terme (PD)
1982	Gatti Foundation Award for young haematologists, Bologna
1981	International Award for medical students, Ascona, Svizzera

Attività Scientifica

L'attività di ricerca del Prof. Pelicci è documentata da 484 articoli su riviste, 32 capitoli di libri. H-Index pari a 102 (Scopus database). Il Prof. Pelicci è titolare di 10 brevetti.

I principali temi dell'attività scientifica sono i seguenti:

- Meccanismi del riarrangiamento dei geni delle immunoglobuline e del recettore delle cellule T e loro impiego nella diagnostica dei disordini linfoproliferativi.
- Analisi delle alterazioni genetiche delle cellule neoplastiche ed interpretazione delle stesse in termini di patogenesi della trasformazione e marcatori tumorali specifici. In particolare, studio delle alterazioni degli oncogeni c-myc e c-myb nei linfomi e delle alterazioni del gene RAR α nella leucemia acuta promielocitica.
- Studi clinici e biologici sulla terapia differenziativa con Acido Retinoico delle Leucemie Acute Mieloblastiche e di alcune neoplasie solide.

- d) Clonaggio del gene Shc e definizione del ruolo della proteina SHC nella trasduzione del segnale da tirosin-chinasi attivate a Ras.
- e) Meccanismi genetici dell'invecchiamento.
- f) Ruolo dell'inibitore del ciclo cellulare p21 nel *self-renewal* delle cellule staminali leucemiche.
- g) Meccanismi molecolari di divisione simmetrica e asimmetrica in cellule staminali mammarie.

Brevetti

1. Group of genomic probes for use in the diagnosis of acute promyelocytic leukaemia and as a component of a diagnostic kit. IT1244704 (B), 1994-08-08.
2. Intracellular interactors and EH domain binding specificity. IT1291110 (B1), 1998-12-29
3. Materials and methods relating to modulation of P66 expression. EP1163335 (B1), 2005-05-25; AU778301 (B2), 2004-11-25.
4. Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease. AU2007207869 (B2), 2009-09-10
5. Valproic acid for the treatment of breast cancer, colon cancer, head and neck cancer, small cell lung carcinoma and cancer of the blood cells in combination with irradiation EP1427403 (B1), 2005-12-28; EP1427403 (B8), 2006-03-22; AU2002338716 (B2), 2007-08-16
6. Topical use of valproic acid for the prevention or treatment of psoriasis and acne. EP1635808 (B1), 2008-10-01
7. Antibody tools for the diagnostic use in the medical therapy with inhibitors of histone deacetylases. US7858329 (B2), 2010-12-28; JP4738810 (B2), 2011-08-03.
8. Histone Deacetylases Inhibitors. US7803800 (B2), 2010-09-28; AU2005291297 (B2), 2010-12-23; US8058273 (B2), 2011-11-15; CN101039905 (B), 2012-02-08.
9. The use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity. AU2003267386 (B2), 2010-07-01.
10. Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting MPT. US7915304 (B2), 2011-03-29.

Pubblicazioni

2018

1. Sarmiento MJ, Oneto M, Pelicci S, Pesce L, Scipioni L, Faretta M, Furia L, Dellino GI, **Pelicci PG**, Bianchini P, Diaspro A, Lanza L. *Exploiting the tunability of stimulated emission depletion microscopy for super-resolution imaging of nuclear structures*. Nat Commun. 2018 Aug 24.
2. Onnis A, Cianfanelli V, Cassioli C, Samardzic D, **Pelicci PG**, Cecconi F, Baldari CT. *The pro-oxidant adaptor p66SHC promotes B cell mitophagy by disrupting mitochondrial integrity and recruiting LC3-II*. Autophagy. 2018 Aug 15.
3. Bonetti P, Climent M, Panebianco F, Tordonato C, Santoro A, Marzi MJ, **Pelicci PG**, Ventura A, Nicassio F. *Dual role for miR-34a in the control of early progenitor proliferation and commitment in the mammary gland and in breast cancer*. Oncogene. 2018 Aug 9.
4. Ghelli Luserna Di Rorà A, Beeharri N, Imbrogno E, Ferrari A, Robustelli V, Righi S, Sabattini E, Verga Falzacappa MV, Ronchini C, Testoni N, Baldazzi C, Papayannidis C, Abbenante MC, Marconi G, Paolini S, Parisi S, Sartor C, Fontana MC, De Matteis S, Iacobucci I, **Pelicci PG**, Cavo M, Yen TJ, Martinelli G. *Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia*. J Hematol Oncol. 2018 Aug 1.
5. Melloni, Guida, Curigliano, Botteri, Esposito, Kamal, Le Tourneau, Riva, Magi, de Maria, **Pelicci PG**, Mazzarella. *Precision Trial Drawer (PTD), a computational tool to assist planning of genomics-driven trials in oncology*. Annals of Oncology. 2018. In press
6. Palmigiano A, Santaniello F, Cerutti A, Penkov D, Purushothaman D, Makhija E, Luzi L, di Fagagna FD, **Pelicci PG**, Shivashankar V, Dellino GI, Blasi F. *PREP1 tumor suppressor protects the late-replicating DNA by controlling its replication timing and symmetry*. Sci Rep. 2018 Feb 16;8(1):3198.
7. Patrucci L, Capitani N, Cattaneo F, Manganaro N, Gamberucci A, Frezzato F, Martini V, Visentin A, **Pelicci PG**, D'Elia MM, Trentin L, Semenzato G, Baldari CT. *p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from β -arrestin at early endosomes*. Oncogene. 2018 Jan 12.

2017

8. Sanarico AG, Ronchini C, Croce A, Memmi EM, Cammarata UA, De Antoni A, Lavorgna S, Divona M, Giacobè L, Melloni GEM, Brendolan A, Simonetti G, Martinelli G, Mancuso P, Bertolini F, Coco FL, Melino G, **Pelicci PG**, Bernassola F. *The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemia*. Leukemia. 2017 Dec 6.
9. A. Soldà A, Valenti G, Marcaccio M, Giorgio M, **Pelicci PG**, Paolucci F, Rapino S. *Glucose and Lactate Miniaturized Biosensors for SECM-Based High-Spatial Resolution Analysis: A Comparative Study*. ACS Sens. 2017 Sep 22;2(9):1310-1318.
10. TrabANELLI S, Chevalier MF, Martinez-Usatorre A, Gomez-Cadena A, Salomé B, Lecciso M, Salvestrini V, Verdeil G, Racle J, Papayannidis C, Morita H, Pizzitola I, Grandclément C, Bohner P, Bruni E, Girotra M, Pallavi R, Falvo P, Leibundgut EO, Baerlocher GM, Carlo-Stella C, Taurino D, Santoro A, Spinelli O, Rambaldi A, Giarin E, Basso G, Tresoldi C, Ciceri F, Gfeller D, Akdis CA, Mazzarella L, Minucci S, **Pelicci PG**, Marcenaro E, McKenzie ANJ, Vanhecke D, Coukos G, Mavilio D, Curti A, Derré L, Jandus C. *Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis*. Nat Commun. 2017 Sep 19;8(1):593.
11. Byrne AT, Alferez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mølandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, **Pelicci PG**, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L. *Interrogating open issues in cancer medicine with patient-derived xenografts*. Nat Rev Cancer. 2017 Sep 15;17(10):632.
12. Ronchini C, Brozzi A, Riva L, Luzi L, Gruszka AM, Melloni GEM, Scanziani E, Dharmalingam G, Mutarelli M, Belcastro V, Lavorgna S, Rossi V, Spinelli O, Biondi A, Rambaldi A, Lo-Coco F, di Bernardo D, **Pelicci PG**. *PML-RARA-associated cooperating mutations belong to a transcriptional network that is deregulated in myeloid leukemias*. Leukemia. 2017 Sep;31(9):1975-1986.
13. Richichi C, Fornasari L, Melloni GEM, Brescia P, Patanè M, Del Bene M, Mustafa DAM, Kros JM, Pollo B, Pruneri G, Sciandivasci A, Munzone E, DiMeco F, **Pelicci PG**, Riva L, Pelicci G. *Mutations targeting the coagulation pathway are enriched in brain metastases*. Sci Rep. 2017 Jul 26;7(1):6573.
14. Di Malta C, Siciliano D, Calcagni A, Monfregola J, Punzi S, Pastore N, Eastes AN, Davis O, De Cegli R, Zampelli A, Di Giovannantonio LG, Nusco E, Platt N, Guida A, Ogmundsdottir MH, Lanfrancone L, Perera RM, Zoncu R, **Pelicci PG**, Settembre C, Ballabio A. *Transcriptional activation of RagD GTPase controls mTORC1 and promotes cancer growth*. Science. 2017 Jun 16;356(6343):1188-1192.
15. Melloni GEM, Mazzarella L, Bernard L, Bodini M, Russo A, Luzi L, **Pelicci PG**, Riva L. *A knowledge-based framework for the discovery of cancer-predisposing variants using large-scale sequencing breast cancer data*. Breast Cancer Res. 2017 May 31;19(1):63.
16. Amato A, Aringhieri E, Boccia S, Buccella F, Gorini B, Gramaglia D, Masetti R, Rossi P, **Pelicci PG**. *A harmonized and efficient clinical research environment would benefit patients and enhance European competitiveness*. Commentary. Ann Ist Super Sanita. 2017 Apr-Jun;53(2):104-107.
17. Byrne AT, Alferez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mølandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, **Pelicci PG**, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L. *Interrogating open issues in cancer precision medicine with patient-derived xenografts*. Nat Rev Cancer. 2017 Apr;17(4):254-268. Review.
18. Curigliano G, Cardoso F, Costa A, Galimberti V, Goldhirsch A, **Pelicci PG**, Veronesi P, Viale G, Orecchia R. *From the maximum tolerable to the minimum effective treatment: The Umberto Veronesi's life commitment to breast cancer care*. Breast. 2017 Feb;31:241-243.
19. Favarsani A, Amatori S, Augello C, Colombo F, Porretti L, Fanelli M, Ferrero S, Palleschi A, **Pelicci PG**, Belloni E, Ercoli G, Degraffi A, Baccarin M, Altieri DC, Vaira V, Bosari S. *miR-494-3p is a novel tumor driver of lung carcinogenesis*. Oncotarget. 2017 Jan 31;8(5):7231-7247.

2016

20. D'Alesio C, Punzi S, Cicalese A, Fornasari L, Furia L, Riva L, Carugo A, Curigliano G, Criscitiello C, Pruneri G, **Pelicci PG**, Faretta M, Bossi D, Lanfrancone L. *RNAi screens identify CHD4 as an essential gene in breast cancer growth*. Oncotarget. 2016 Dec 6;7(49):80901-80915.

21. Santoro A, Vlachou T, Carminati M, **Pelicci PG**, Mapelli M. *Molecular mechanisms of asymmetric divisions in mammary stem cells*. *EMBO Rep*. 2016 Dec;17(12):1700-1720. Review.
22. Stunnenberg HG; International Human Epigenome Consortium, Hirst M. *The International Human Epigenome Consortium: A Blueprint for Scientific Collaboration and Discovery*. *Cell*. 2016 Nov 17;167(5):1145-1149.
23. Rossi A, Ferrari KJ, Piunti A, Jammula S, Chiacchiera F, Mazzarella L, Scelfo A, **Pelicci PG**, Pasini D. *Maintenance of leukemic cell identity by the activity of the Polycomb complex PRC1 in mice*. *Sci Adv*. 2016 Oct 7;2(10):e1600972.
24. Bigi A, Beltrami E, Trinei M, Stendardo M, **Pelicci PG**, Giorgio M. *Cyclophilin D counteracts P53-mediated growth arrest and promotes Ras tumorigenesis*. *Oncogene*. 2016 Sep 29;35(39):5132-43.
25. Carugo A, Genovese G, Seth S, Nezi L, Rose JL, Bossi D, Cicalese A, Shah PK, Viale A, Pettazzoni PF, Akdemir KC, Bristow CA, Robinson FS, Tepper J, Sanchez N, Gupta S, Estecio MR, Giuliani V, Dellino GI, Riva L, Yao W, Di Francesco ME, Green T, D'Alesio C, Corti D, Kang Y, Jones P, Wang H, Fleming JB, Maitra A, **Pelicci PG**, Chin L, DePinho RA, Lanfrancone L, Heffernan TP, Draetta GF. *In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer*. *Cell Rep*. 2016 Jun 28;16(1):133-147.
26. Tomilov A, Tomilova N, Shan Y, Hagopian K, Bettaieb A, Kim K, **Pelicci PG**, Haj F, Ramsey J, Cortopassi G. *p46Shc Inhibits Thiolase and Lipid Oxidation in Mitochondria*. *J Biol Chem*. 2016 Jun 10;291(24):12575-85.
27. Giorgio M, Stendardo M, Migliaccio E, **Pelicci PG**. *P66SHC deletion improves fertility and progeric phenotype of late-generation TERC-deficient mice but not their short lifespan*. *Aging Cell*. 2016 Jun;15(3):446-54.
28. Marchesini M, Matocci R, Tasselli L, Cambiaghi V, Orleth A, Furia L, Marinelli C, Lombardi S, Sammarelli G, Aversa F, Minucci S, Faretta M, **Pelicci PG**, Grignani F. *PML is required for telomere stability in non-neoplastic human cells*. *Oncogene*. 2016 Apr 7;35(14):1876.
29. Marchesini M, Matocci R, Tasselli L, Cambiaghi V, Orleth A, Furia L, Marinelli C, Lombardi S, Sammarelli G, Aversa F, Minucci S, Faretta M, **Pelicci PG**, Grignani F. *PML is required for telomere stability in non-neoplastic human cells*. *Oncogene*. 2016 Apr 7;35(14):1811-21.
30. Ambrosio S, Di Palo G, Napolitano G, Amente S, Dellino GI, Faretta M, **Pelicci PG**, Lania L, Majello B. *Cell cycle-dependent resolution of DNA double-strand breaks*. *Oncotarget*. 2016 Jan 26;7(4):4949-60.

2015

31. Iacobucci I, Di Rorà AG, Falzacappa MV, Agostinelli C, Derenzini E, Ferrari A, Papayannidis C, Lonetti A, Righi S, Imbrogno E, Pomella S, Venturi C, Guadagnuolo V, Cattina F, Ottaviani E, Abbenante MC, Vitale A, Elia L, Russo D, Zinzani PL, Pileri S, **Pelicci PG**, Martinelli G. *In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia*. *J Hematol Oncol*. 2015 Nov 5;8:125.
32. Cremona MA, Sangalli LM, Vantini S, Dellino GI, **Pelicci PG**, Secchi P, Riva L. *Peak shape clustering reveals biological insights*. *BMC Bioinformatics*. 2015 Oct 28;16:349.
33. Magnabosco G, Di Giosia M, Polishchuk I, Weber E, Fermani S, Bottoni A, Zerbetto F, **Pelicci PG**, Pokroy B, Rapino S, Falini G, Calvaresi M. *Calcite single crystals as hosts for atomic-scale entrapment and slow release of drugs*. *Adv Healthc Mater*. 2015 Sep 16;4(13):1899.
34. Bräuer-Hartmann D, Hartmann JU, Wurm AA, Gerloff D, Katzerke C, Verga Falzacappa MV, **Pelicci PG**, Müller-Tidow C, Tenen DG, Niederwieser D, Behre G. *PML/RAR α -Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia*. *Cancer Res*. 2015 Aug 15;75(16):3411-24.
35. Melino G, Memmi EM, **Pelicci PG**, Bernassola F. *Maintaining epithelial stemness with p63*. *Sci Signal*. 2015 Jul 28;8(387):re9. Review.
36. Magnabosco G, Di Giosia M, Polishchuk I, Weber E, Fermani S, Bottoni A, Zerbetto F, **Pelicci PG**, Pokroy B, Rapino S, Falini G, Calvaresi M. *Calcite Single Crystals as Hosts for Atomic-Scale Entrapment and Slow Release of Drugs*. *Adv Healthc Mater*. 2015 Jul 15;4(10):1510-6.
37. Chiaradonna F, Barozzi I, Miccolo C, Bucci G, Palorini R, Fornasari L, Botrugno OA, Pruneri G, Masullo M, Passafaro A, Galimberti VE, Fantin VR, Richon VM, Pece S, Viale G, Di Fiore PP, Draetta G, **Pelicci PG**, Minucci S, Chiocca S. *Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer*. *Antioxid Redox Signal*. 2015 Jul 1;23(1):15-29.
38. Belloni E, Veronesi G, Rotta L, Volorio S, Sardella D, Bernard L, Pece S, Di Fiore PP, Fumagalli C, Barberis M, Spaggiari L, **Pelicci PG**, Riva L. *Whole exome sequencing identifies driver mutations in asymptomatic computed tomography-detected lung cancers with normal karyotype*. *Cancer Genet*. 2015 Apr;208(4):152-5.

39. Falzacappa MV, Ronchini C, Faretta M, Iacobucci I, Di Rorà AG, Martinelli G, Meyer LH, Debatin KM, Orecchioni S, Bertolini F, **Pelicci PG**. *The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias*. Mol Cancer Ther. 2015 Apr;14(4):889-98.
 40. Memmi EM, Sanarico AG, Giacobbe A, Peschiaroli A, Frezza V, Cicalese A, Pisati F, Tosoni D, Zhou H, Tonon G, Antonov A, Melino G, **Pelicci PG**, Bernassola F. *p63 Sustains self-renewal of mammary cancer stem cells through regulation of Sonic Hedgehog signaling*. Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3499-504.
 41. Priami C, De Michele G, Cotelli F, Cellerino A, Giorgio M, **Pelicci PG**, Migliaccio E. *Modelling the p53/p66Shc Aging Pathway in the Shortest Living Vertebrate Nothobranchius Furzeri*. Aging Dis. 2015 Mar 10;6(2):95-108. Review
 42. Bodini M, Ronchini C, Giacò L, Russo A, Melloni GE, Luzi L, Sardella D, Volorio S, Hasan SK, Ottone T, Lavorgna S, Lo-Coco F, Candoni A, Fanin R, Toffoletti E, Iacobucci I, Martinelli G, Cignetti A, Tarella C, Bernard L, **Pelicci PG**, Riva L. *The hidden genomic landscape of acute myeloid leukemia: subclonal structure revealed by undetected mutations*. Blood. 2015 Jan 22;125(4):600-5. Review.
-
- 2014
43. Ramsey JJ, Tran D, Giorgio M, Griffey SM, Koehne A, Laing ST, Taylor SL, Kim K, Cortopassi GA, Lloyd KC, Hagopian K, Tomilov AA, Migliaccio E, **Pelicci PG**, McDonald RB. *The influence of Shc proteins on life span in mice*. J Gerontol A Biol Sci Med Sci. 2014 Oct;69(10):1177-85.
 44. Mazzarella L, Riva L, Luzi L, Ronchini C, **Pelicci PG**. *The genomic and epigenomic landscapes of AML*. Semin Hematol. 2014 Oct;51(4):259-72.
 45. Bellisario V, Berry A, Capoccia S, Raggi C, Panetta P, Branchi I, Piccaro G, Giorgio M, **Pelicci PG**, Cirulli F. *Gender-dependent resiliency to stressful and metabolic challenges following prenatal exposure to high-fat diet in the p66(Shc-/-) mouse*. Front Behav Neurosci. 2014 Aug 22;8:285.
 46. Amatori S, Ballarini M, Faversani A, Belloni E, Fusar F, Bosari S, **Pelicci PG**, Minucci S, Fanelli M. *PAT-ChIP coupled with laser microdissection allows the study of chromatin in selected cell populations from paraffin-embedded patient samples*. Epigenetics Chromatin. 2014 Aug 5;7:18.
 47. Testori A, Ascierto P, Chiarion Sileni V, De Lorenzo F, Pelicci P, Rossi C. *Report from the Melanoma Independent Board First Melanoma MIB Conference, 21-22 October 2013*. Ecancermedalscience. 2014 Jun 30;8:440.
 48. Fancelli D, Abate A, Amici R, Bernardi P, Ballarini M, Cappa A, Carenzi G, Colombo A, Contursi C, Di Lisa F, Dondio G, Gagliardi S, Milanese E, Minucci S, Pain G, **Pelicci PG**, Saccani A, Storto M, Thaler F, Varasi M, Villa M, Plyte S. *Cinnamic anilides as new mitochondrial permeability transition pore inhibitors endowed with ischemia-reperfusion injury protective effect in vivo*. J Med Chem. 2014 Jun 26;57(12):5333-47.
 49. Melloni GE, Ogier AG, de Pretis S, Mazzarella L, Pelizzola M, **Pelicci PG**, Riva L. *DOTS-Finder: a comprehensive tool for assessing driver genes in cancer genomes*. Genome Med. 2014 Jun 10;6(6):44.
 50. Raule N, Sevini F, Li S, Barbieri A, Tallaro F, Lomartire L, Vianello D, Montesanto A, Moilanen JS, Bezrukov V, Blanché H, Hervonen A, Christensen K, Deiana L, Gonos ES, Kirkwood TB, Kristensen P, Leon A, **Pelicci PG**, Poulain M, Rea IM, Remacle J, Robine JM, Schreiber S, Sikora E, Eline Slagboom P, Spazzafumo L, Antonietta Stazi M, Toussaint O, Vaupel JW, Rose G, Majamaa K, Perola M, Johnson TE, Bolund L, Yang H, Passarino G, Franceschi C. *The co-occurrence of mtDNA mutations on different oxidative phosphorylation subunits, not detected by haplogroup analysis, affects human longevity and is population specific*. Aging Cell. 2014 Jun;13(3):401-7.
 51. Martinelli C, Colombo E, Piccini D, Sironi C, **Pelicci PG**, de Marco A. *An intrabody specific for the nucleophosmin carboxy-terminal mutant and fused to a nuclear localization sequence binds its antigen but fails to relocate it in the nucleus*. Biotechnol Rep (Amst). 2014 May 27;3:27-33.
 52. Cevenini E, Cotichini R, Stazi MA, Toccaceli V, Palmas MG, Capri M, De Rango F, Dato S, Passarino G, Jeune B, Franceschi C; *Health status and 6 years survival of 552 90+ Italian sib-ships recruited within the EU Project GEHA (Genetics of Healthy Ageing)*. GEHA Project Consortium. Age (Dordr). 2014 Apr;36(2):949-66.
 53. Insinga A, Cicalese A, **Pelicci PG**. *DNA damage response in adult stem cells*. Blood Cells Mol Dis. 2014 Apr;52(4):147-51.
 54. Riva L, Ronchini C, Bodini M, Lo-Coco F, Lavorgna S, Ottone T, Martinelli G, Iacobucci I, Tarella C, Cignetti A, Volorio S, Bernard L, Russo A, Melloni GE, Luzi L, Alcalay M, Dellino GI, **Pelicci PG**. *Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups*. Blood Cancer J. 2014 Mar 21;4:e195.

55. Toffalorio F, Belloni E, Barberis M, Bucci G, Tizzoni L, Pruneri G, Fumagalli C, Spitaleri G, Catania C, Melotti F, **Pelicci PG**, Spaggiari L, De Pas T. *Gene expression profiling reveals GC and CEACAM1 as new tools in the diagnosis of lung carcinoids*. *Br J Cancer*. 2014 Mar 4;110(5):1244-9.
56. Dellino GI, **Pelicci PG**. *Next-generation sequencing and DNA replication in human cells: the future has arrived*. *Future Oncol*. 2014 Mar;10(4):683-93. Review.
57. Patrussi L, Capitani N, Cannizzaro E, Finetti F, Lucherini OM, **Pelicci PG**, Baldari CT. *Negative regulation of chemokine receptor signaling and B-cell chemotaxis by p66Shc*. *Cell Death Dis*. 2014 Feb 20;5:e1068.
58. Masi G, Mercati D, Vannuccini E, Paccagnini E, Riparbelli MG, Lupetti P, **Pelicci PG**, Baldari CT, Olivieri C. *p66Shc regulates vesicle-mediated secretion in mast cells by affecting F-actin dynamics*. *J Leukoc Biol*. 2014 Feb;95(2):285-92.

2013

59. Campaner S, Viale A, De Fazio S, Doni M, De Franco F, D'Artista L, Sardella D, **Pelicci PG**, Amati B. *A non-redundant function of cyclin E1 in hematopoietic stem cells*. *Cell Cycle*. 2013 Dec 1;12(23):3663-72.
60. Mazzarella L, Disalvatore D, Bagnardi V, Rotmensz N, Galbiati D, Caputo S, Curigliano G, **Pelicci PG**. *Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients*. *Eur J Cancer*. 2013 Nov;49(17):3588-97.
61. Mallardo M, Caronno A, Pruneri G, Raviele PR, Viale A, **Pelicci PG**, Colombo E. *NPMc+ and FLT3 ITD mutations cooperate in inducing acute leukaemia in a novel mouse model*. *Leukemia*. 2013 Nov;27(11):2248-51.
62. Cevenini E, Cotichini R, Stazi MA, Toccaceli V, Scurti M, Mari V, Berardelli M, Passarino G, Jeune B, Franceschi C. *How to classify the oldest old according to their health status: a study on 1160 subjects belonging to 552 90+ Italian sib-ships characterized by familial longevity recruited within the GEHA EU Project*. GEHA Project Consortium. *Mech Ageing Dev*. 2013 Nov-Dec;134(11-12):560-9.
63. Riva L, Ronchini C, Bodini M, Lo-Coco F, Lavorgna S, Ottone T, Martinelli G, Iacobucci I, Tarella C, Cignetti A, Volorio S, Bernard L, Russo A, Melloni GE, Luzi L, Alcalay M, Dellino GI, **Pelicci PG**. *Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups*. *Blood Cancer J*. 2013 Sep 13;3:e147.
64. Napolitano G, Amente S, Lavadera ML, Di Palo G, Ambrosio S, Lania L, Dellino GI, **Pelicci PG**, Majello B. *Sequence-specific double strand breaks trigger P-TEFb-dependent Rpb1-CTD hyperphosphorylation*. *Mutat Res*. 2013 Sep;749(1-2):21-7.
65. Castelli M, Pieroni S, Brunacci C, Piobbico D, Bartoli D, Bellet MM, Colombo E, **Pelicci PG**, Della Fazio MA, Servillo G. *Hepatocyte odd protein shuttling (HOPS) is a bridging protein in the nucleophosmin-p19 Arf network*. *Oncogene*. 2013 Jul 11;32(28):3350-8.
66. Mazza M, **Pelicci PG**. *Is PML a Tumor Suppressor?* *Front Oncol*. 2013 Jul 9;3:174.
67. Migliaccio E, Giorgio M, **Pelicci PG**. *p53 and aging: role of p66Shc*. *Aging (Albany NY)*. 2013 Jul;5(7):488-9.
68. **Pelicci PG**, Dalton P, Giorgio M. *The other face of ROS: a driver of stem cell expansion in colorectal cancer*. *Cell Stem Cell*. 2013 Jun 6;12(6):635-6.
69. Gambino V, De Michele G, Venezia O, Migliaccio P, Dall'Olio V, Bernard L, Minardi SP, Della Fazio MA, Bartoli D, Servillo G, Alcalay M, Luzi L, Giorgio M, Scrabble H, **Pelicci PG**, Migliaccio E. *Oxidative stress activates a specific p53 transcriptional response that regulates cellular senescence and aging*. *Aging Cell*. 2013 Jun;12(3):435-45.
70. Santoro F, Botrugno OA, Dal Zuffo R, Pallavicini I, Matthews GM, Cluse L, Barozzi I, Senese S, Fornasari L, Moretti S, Altucci L, **Pelicci PG**, Chiocca S, Johnstone RW, Minucci S. *A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance*. *Blood*. 2013 Apr 25;121(17):3459-68.
71. Beltrami E, Ruggiero A, Busuttil R, Migliaccio E, **Pelicci PG**, Vijg J, Giorgio M. *Deletion of p66Shc in mice increases the frequency of size-change mutations in the lacZ transgene*. *Aging Cell*. 2013 Apr;12(2):177-83.
72. Furia L, **Pelicci PG**, Faretta M. *A computational platform for robotized fluorescence microscopy (I): high-content image-based cell-cycle analysis*. *Cytometry A*. 2013 Apr;83(4):333-43.
73. Furia L, **Pelicci PG**, Faretta M. *A computational platform for robotized fluorescence microscopy (II): DNA damage, replication, checkpoint activation, and cell cycle progression by high-content high-resolution multiparameter image-cytometry*. *Cytometry A*. 2013 Apr;83(4):344-55.
74. Insinga A, Cicalese A, Faretta M, Gallo B, Albano L, Ronzoni S, Furia L, Viale A, **Pelicci PG**. *DNA damage in stem cells activates p21, inhibits p53, and induces symmetric self-renewing divisions*. *Proc Natl Acad Sci U S A*. 2013 Mar 5;110(10):3931-6.

75. Bock F, Shahzad K, Wang H, Stoyanov S, Wolter J, Dong W, **Pelicci PG**, Kashif M, Ranjan S, Schmidt S, Ritzel R, Schwenger V, Reymann KG, Esmon CT, Madhusudhan T, Nawroth PP, Isermann B. *Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc*. Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):648-53.
76. Dellino GI, Cittaro D, Piccioni R, Luzi L, Banfi S, Segalla S, Cesaroni M, Mendoza-Maldonado R, Giacca M, **Pelicci PG**. *Genome-wide mapping of human DNA-replication origins: levels of transcription at ORC1 sites regulate origin selection and replication timing*. Genome Res. 2013 Jan;23(1):1-11.

2012

77. Vashistha H, Singhal PC, Malhotra A, Husain M, Mathieson P, Saleem MA, Kuriakose C, Seshan S, Wilk A, Delvalle L, Peruzzi F, Giorgio M, **Pelicci PG**, Smithies O, Kim HS, Kakoki M, Reiss K, Meggs LG. *Null mutations at the p66 and bradykinin 2 receptor loci induce divergent phenotypes in the diabetic kidney*. Am J Physiol Renal Physiol. 2012 Dec 15;303(12):F1629-40.
78. Berry A, Amrein I, Nötzli S, Lazic SE, Bellisario V, Giorgio M, **Pelicci PG**, Alleva E, Lipp HP, Cirulli F. *Sustained hippocampal neurogenesis in females is amplified in P66(Shc^{-/-}) mice: An animal model of healthy aging*. Hippocampus. 2012 Dec;22(12):2249-59.
79. Verga Falzacappa MV, Ronchini C, Reavie LB, **Pelicci PG**. *Regulation of self-renewal in normal and cancer stem cells*. FEBS J. 2012 Oct;279(19):3559-3572.
80. Pallavi R, Giorgio M, **Pelicci PG**. *Insights into the beneficial effect of caloric/ dietary restriction for a healthy and prolonged life*. Front Physiol. 2012 Aug 9;3:318.
81. Salamone F, Li Volti G, Titta L, Puzzo L, Barbagallo I, La Delia F, Zelber-Sagi S, Malaguarnera M, **Pelicci PG**, Giorgio M, Galvano F. *Moro orange juice prevents fatty liver in mice*. World J Gastroenterol. 2012 Aug 7;18(29):3862-8.
82. **Pelicci PG**. *Normal and leukemic stem cells*. Leuk Suppl. 2012 Aug;1(Suppl 2):S54-5.
83. Marcu R, Rapino S, Trinei M, Valenti G, Marcaccio M, **Pelicci PG**, Paolucci F, Giorgio M. *Electrochemical study of hydrogen peroxide formation in isolated mitochondria*. Bioelectrochemistry. 2012 Jun;85:21-8.
84. Riva L, Luzi L, **Pelicci PG**. *Genomics of acute myeloid leukemia: the next generation*. Front Oncol. 2012 May 1;2:40.
85. BLUEPRINT to decode the epigenetic signature written in blood. Adams D, Altucci L, Antonarakis SE, Ballesteros J, Beck S, Bird A, Bock C, Boehm B, Campo E, Caricasole A, Dahl F, Dermitzakis ET, Enver T, Esteller M, Estivill X, Ferguson-Smith A, Fitzgibbon J, Flicek P, Giehl C, Graf T, Grosveld F, Guigo R, Gut I, Helin K, Jarvius J, Küppers R, Lehrach H, Lengauer T, Lernmark Å, Leslie D, Loeffler M, Macintyre E, Mai A, Martens JH, Minucci S, Ouwehand WH, **Pelicci PG**, Pendeville H, Porse B, Rakyan V, Reik W, Schrappe M, Schübeler D, Seifert M, Siebert R, Simmons D, Soranzo N, Spicuglia S, Stratton M, Stunnenberg HG, Tanay A, Torrents D, Valencia A, Vellenga E, Vingron M, Walter J, Willcocks S. Nat Biotechnol. 2012 Mar 7;30(3):224-6.
86. Giorgio M, Berry A, Berniakovich I, Poletaeva I, Trinei M, Stendardo M, Hagopian K, Ramsey JJ, Cortopassi G, Migliaccio E, Nötzli S, Amrein I, Lipp HP, Cirulli F, **Pelicci PG**. *The p66Shc knocked out mice are short lived under natural condition*. Aging Cell. 2012 Feb;11(1):162-8.
87. Breccia M, Mazzarella L, Bagnardi V, Disalvatore D, Loglisci G, Cimino G, Testi AM, Avvisati G, Petti MC, Minotti C, Latagliata R, Foà R, **Pelicci PG**, Lo-Coco F. *Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols*. Blood. 2012 Jan 5;119(1):49-54.
88. Cambiaghi V, Giuliani V, Lombardi S, Marinelli C, Toffalorio F, **Pelicci PG**. *TRIM proteins in cancer*. Adv Exp Med Biol. 2012;770:77-91. Review.
89. Gruszka AM, Martinelli C, Sparacio E, **Pelicci PG**, de Marco A. *The concurrent use of N- and C-terminal antibodies anti-nucleophosmin 1 in immunofluorescence experiments allows for precise assessment of its subcellular localisation in acute myeloid leukaemia patients*. Leukemia. 2012 Jan;26(1):159-62.
90. Bonizzi G, Cicalese A, Insinga A, **Pelicci PG**. *The emerging role of p53 in stem cells*. Trends Mol Med. 2012 Jan;18(1):6-12.

2011

91. Pesaresi MG, Amori I, Giorgi C, Ferri A, Fiorenzo P, Gabanella F, Salvatore AM, Giorgio M, **Pelicci PG**, Pinton P, Carri MT, Cozzolino M. *Mitochondrial redox signalling by p66Shc mediates ALS-like disease through Rac1 inactivation*. Hum Mol Genet. 2011 Nov 1;20(21):4196-208.
92. Pasi CE, **Pelicci PG**. *Inhibition of epithelial-to-mesenchymal transition: a novel tumor suppressor function of p53?* Cell Cycle. 2011 Aug 15;10(16):2616-7.

93. Martinelli P, Bonetti P, Sironi C, Pruneri G, Fumagalli C, Raviele PR, Volorio S, Pileri S, Chiarle R, McDuff FK, Tusi BK, Turner SD, Inghirami G, **Pelicci PG**, Colombo E. *The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway.* Blood. 2011 Jun 16;117(24):6617-26.
 94. Colombo E, Alcalay M, **Pelicci PG**. *Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases.* Oncogene. 2011 Jun 9;30(23):2595-609. Review.
 95. **Pelicci PG**, Dalton P, Orecchia R. *Heating cancer stem cells to reduce tumor relapse.* Breast Cancer Res. 2011 May 6;13(3):305.
 96. Pasi CE, Dereli-Öz A, Negrini S, Friedli M, Fragola G, Lombardo A, Van Houwe G, Naldini L, Casola S, Testa G, Trono D, **Pelicci PG**, Halazonetis TD. *Genomic instability in induced stem cells.* Cell Death Differ. 2011 May;18(5):745-53.
 97. Ulivieri C, Fanigliulo D, Masi G, Savino MT, Gamberucci A, **Pelicci PG**, Baldari CT. *p66Shc is a negative regulator of FcεRI-dependent signaling in mast cells.* J Immunol. 2011 May 1;186(9):5095-106.
 98. Occhionorelli M, Santoro F, Pallavicini I, Gruszka A, Moretti S, Bossi D, Viale A, Shing D, Ronzoni S, Muradore I, Soncini M, Pruneri G, Rafaniello P, Viale G, **Pelicci PG**, Minucci S. *The self-association coiled-coil domain of PML is sufficient for the oncogenic conversion of the retinoic acid receptor (RAR) alpha.* Leukemia. 2011 May;25(5):814-20.
 99. Gadad SS, Senapati P, Syed SH, Rajan RE, Shandilya J, Swaminathan V, Chatterjee S, Colombo E, Dimitrov S, **Pelicci PG**, Ranga U, Kundu TK. *The multifunctional protein nucleophosmin (NPM1) is a human linker histone H1 chaperone.* Biochemistry. 2011 Apr 12;50(14):2780-9.
 100. Belloni E, Shing D, Tapinassi C, Viale A, Mancuso P, Malazzi O, Gerbino E, Dall'Olio V, Egurbide I, Otero MD, Bertolini F, **Pelicci PG**. *In vivo expression of an aberrant MYB-GATA1 fusion induces leukemia in the presence of GATA1 reduced levels.* Leukemia. 2011 Apr;25(4):733-6.
 101. Belloni E, Veronesi G, Micucci C, Javan S, Minardi SP, Venturini E, Maisonneuve P, Volorio S, Riboni M, Belloni M, Scanagatta P, Taliento G, Pelosi G, Pece S, Spaggiari L, **Pelicci PG**. *Genomic characterization of asymptomatic CT-detected lung cancers.* Oncogene. 2011 Mar 3;30(9):1117-26.
 102. Lunardi A, Gaboli M, Giorgio M, Rivi R, Bygrave A, Antoniou M, Drabek D, Dzierzak E, Fagioli M, Salmena L, Botto M, Cordon-Cardo C, Luzzatto L, **Pelicci PG**, Grosveld F, Pandolfi PP. *A Role for PML in Innate Immunity.* Genes Cancer. 2011 Jan;2(1):10-9.
-
- 2010
103. Fanelli M, Amatori S, Barozzi I, Soncini M, Dal Zuffo R, Bucci G, Capra M, Quarto M, Dellino GI, Mercurio C, Alcalay M, Viale G, **Pelicci PG**, Minucci S. *Pathology tissue-chromatin immunoprecipitation, coupled with high-throughput sequencing, allows the epigenetic profiling of patient samples.* Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21535-40.
 104. Rose G, Romeo G, Dato S, Crocco P, Bruni AC, Hervonen A, Majamaa K, Sevini F, Franceschi C, Passarino G; GENetics of Healthy Ageing Project Consortium. *Somatic point mutations in mtDNA control region are influenced by genetic background and associated with healthy aging: a GEHA study.* PLoS One. 2010 Oct 14;5(10):e13395.
 105. Differential cytogenomics and miRNA signature of the Acute Myeloid Leukaemia Kasumi-1 cell line CD34+38- compartment. Pedranzini L, Mottadelli F, Ronzoni S, Rossella F, Ferracin M, Magnani I, Roversi G, Colapietro P, Negrini M, **Pelicci PG**, Larizza L. Leuk Res. 2010 Oct;34(10):1287-95.
 106. Gruszka AM, Lavorgna S, Consalvo MI, Ottone T, Martinelli C, Cinquanta M, Ossolengo G, Pruneri G, Buccisano F, Divona M, Cedrone M, Ammatuna E, Venditti A, de Marco A, Lo-Coco F, **Pelicci PG**. *A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias.* Blood. 2010 Sep 23;116(12):2096-102.
 107. Fadini GP, Albiero M, Menegazzo L, Boscaro E, Pagnin E, Iori E, Cosma C, Lapolla A, Pengo V, Stendardo M, Agostini C, **Pelicci PG**, Giorgio M, Avogaro A. *The redox enzyme p66Shc contributes to diabetes and ischemia-induced delay in cutaneous wound healing.* Diabetes. 2010 Sep;59(9):2306-14.
 108. Histone deacetylases and epigenetic therapies of hematological malignancies. Mercurio C, Minucci S, **Pelicci PG**. Pharmacol Res. 2010 Jul;62(1):18-34. Review.
 109. Capitani N, Lucherini OM, Sozzi E, Ferro M, Giommoni N, Finetti F, De Falco G, Cencini E, Raspadori D, **Pelicci PG**, Lauria F, Forconi F, Baldari CT. *Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia.* Blood. 2010 May 6;115(18):3726-36.
 110. Berry A, Carnevale D, Giorgio M, **Pelicci PG**, de Kloet ER, Alleva E, Minghetti L, Cirulli F. *Greater resistance to inflammation at adulthood could contribute to extended life span of p66(Shc-/-) mice.* Exp Gerontol. 2010 May;45(5):343-50.

111. Titta L, Trinei M, Stendardo M, Berniakovich I, Petroni K, Tonelli C, Riso P, Porrini M, Minucci S, **Pelicci PG**, Rapisarda P, Reforgiato Recupero G, Giorgio M. *Blood orange juice inhibits fat accumulation in mice*. Int J Obes (Lond). 2010 Mar;34(3):578-88.
112. Naldini A, Morena E, Pucci A, Pellegrini M, Baldari CT, **Pelicci PG**, Presta M, Ribatti D, Carraro F. *The adaptor protein p66Shc is a positive regulator in the angiogenic response induced by hypoxic T cells*. Leukoc Biol. 2010 Mar;87(3):365-9.
113. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, Bernard L, Viale G, **Pelicci PG**, Di Fiore PP. *Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content*. Cell. 2010 Jan 8;140(1):62-73.
114. Decreased superoxide production in macrophages of long-lived p66Shc knock-out mice. Tomilov AA, Bicocca V, Schoenfeld RA, Giorgio M, Migliaccio E, Ramsey JJ, Hagopian K, **Pelicci PG**, Cortopassi GA. J Biol Chem. 2010 Jan 8;285(2):1153-65. doi: 10.1074/jbc.M109.017491. Epub 2009 Nov 5.
115. Belloni E, Trubia M, Gasparini P, Micucci C, Tapinassi C, Confalonieri S, Nuciforo P, Martino B, Lo-Coco F, Di Fiore P, Pelicci P. *Chromosomal rearrangements in acute myeloid leukemia (AML)*. Ecancermedalscience. 2010;4:183.
116. Belloni E, Lahortiga I, Odero M, Di Fiore P, Pelicci P. *Spectral karyotyping (SKY)*. Ecancermedalscience. 2010;4:181.

2009

117. Gerbino E, Tapinassi C, Malazzi O, Micucci C, Calasanz MJ, Beltran-Heredia JM, Gasparini P, Odero MD, **Pelicci PG**, Belloni E. *A novel t(7;13)(p12;q33 approximately q34) in AML-M2*. Cancer Genet Cytogenet. 2009 Dec;195(2):198-200.
118. Amatori S, Papalini F, Lazzarini R, Donati B, Bagaloni I, Rippo MR, Procopio A, **Pelicci PG**, Catalano A, Fanelli M. *Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in malignant pleural mesothelioma (MPM) cells*. Lung Cancer. 2009 Nov;66(2):184-90.
119. Cicalese A, Bonizzi G, Pasi CE, Faretta M, Ronzoni S, Giulini B, Briskin C, Minucci S, Di Fiore PP, **Pelicci PG**. *The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells*. Cell. 2009 Sep 18;138(6):1083-95. doi: 10.1016/j.cell.2009.06.048.
120. Viale A, **Pelicci PG**. *Awaking stem cells from dormancy: growing old and fighting cancer*. EMBO Mol Med. 2009 May;1(2):88-91.
121. Gargiulo G, Levy S, Bucci G, Romanenghi M, Fornasari L, Beeson KY, Goldberg SM, Cesaroni M, Ballarini M, Santoro F, Bezman N, Frigè G, Gregory PD, Holmes MC, Strausberg RL, **Pelicci PG**, Urnov FD, Minucci S. *NA-Seq: a discovery tool for the analysis of chromatin structure and dynamics during differentiation*. Dev Cell. 2009 Mar;16(3):466-81.
122. Marinelli A, Bossi D, **Pelicci PG**, Minucci S. *Redundant function of retinoic acid receptor isoforms in leukemogenesis unravels a prominent function of genome topology and architecture in the selection of mutagenic events in cancer*. Leukemia. 2009 Feb;23(2):417-9.
123. Rocca A, Minucci S, Tosti G, Croci D, Contegno F, Ballarini M, Nolè F, Munzone E, Salmaggi A, Goldhirsch A, **Pelicci PG**, Testori A. *A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma*. Br J Cancer. 2009 Jan 13;100(1):28-36.
124. Viale A, De Franco F, Orleth A, Cambiaghi V, Giuliani V, Bossi D, Ronchini C, Ronzoni S, Muradore I, Monestiroli S, Gobbi A, Alcalay M, Minucci S, **Pelicci PG**. *Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells*. Nature. 2009 Jan 1;457(7225):51-6.

2008

125. Cesaroni M, Cittaro D, Brozzi A, **Pelicci PG**, Luzi L. *CARPET: a web-based package for the analysis of ChIP-chip and expression tiling data*. Bioinformatics. 2008 Dec 15;24(24):2918-20.
126. Berniakovich I, Trinei M, Stendardo M, Migliaccio E, Minucci S, Bernardi P, **Pelicci PG**, Giorgio M. *p66Shc-generated oxidative signal promotes fat accumulation*. J Biol Chem. 2008 Dec 5;283(49):34283-93.
127. Di Micco R, Cicalese A, Fumagalli M, Dobrev M, Verrecchia A, **Pelicci PG**, di Fagagna Fd. *DNA damage response activation in mouse embryonic fibroblasts undergoing replicative senescence and following spontaneous immortalization*. Cell Cycle. 2008 Nov 15;7(22):3601-6.
128. Gardini A, Cesaroni M, Luzi L, Okumura AJ, Biggs JR, Minardi SP, Venturini E, Zhang DE, **Pelicci PG**, Alcalay M. *AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets*. PLoS Genet. 2008 Nov;4(11):e1000275.
129. Tapinassi C, Gerbino E, Malazzi O, Micucci C, Gasparini P, Najera MJ, Calasanz MJ, Odero MD, **Pelicci PG**, Belloni E. *A new dic(7;12)(p12.21;p12.2) chromosome aberration in a case of acute myeloid leukemia*. Cancer Genet Cytogenet. 2008 Sep;185(2):102-5.

130. Martin-Padura I, de Nigris F, Migliaccio E, Mansueto G, Minardi S, Rienzo M, Lerman LO, Stendardo M, Giorgio M, De Rosa G, **Pelicci PG**, Napoli C. *p66Shc deletion confers vascular protection in advanced atherosclerosis in hypercholesterolemic apolipoprotein E knockout mice.* Endothelium. 2008 Sep-Oct;15(5-6):276-87.
 131. Wanzel M, Russ AC, Kleine-Kohlbrecher D, Colombo E, **Pelicci PG**, Eilers M. *A ribosomal protein L23-nucleophosmin circuit coordinates Miz1 function with cell growth.* Nat Cell Biol. 2008 Sep;10(9):1051-61.
 132. Bonetti P, Davoli T, Sironi C, Amati B, **Pelicci PG**, Colombo E. *Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7 gamma.* J Cell Biol. 2008 Jul 14;182(1):19-26.
 133. Lo-Coco F, Cuneo A, Pane F, Cilloni D, Diverio D, Mancini M, Testoni N, Bardi A, Izzo B, Bolli N, La Starza R, Fazi P, Iacobelli S, Piciocchi A, Vignetti M, Amadori S, Mandelli F, **Pelicci PG**, Mecucci C, Falini B, Saglio G; Acute Leukemia Working Party of the GIMEMA group. *Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia.* Haematologica. 2008 Jul;93(7):1017-24.
 134. Finetti F, Pellegrini M, Ulivieri C, Savino MT, Paccagnini E, Ginanneschi C, Lanfranccone L, **Pelicci PG**, Baldari CT. *The proapoptotic and antimitogenic protein p66SHC acts as a negative regulator of lymphocyte activation and autoimmunity.* Blood. 2008 May 15;111(10):5017-27.
 135. Cosentino F, Francia P, Camici GG, **Pelicci PG**, Lüscher TF, Volpe M. *Final common molecular pathways of aging and cardiovascular disease: role of the p66Shc protein.* Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):622-8. Review.
 136. Berry A, Greco A, Giorgio M, **Pelicci PG**, de Kloet R, Alleva E, Minghetti L, Cirulli F. *Deletion of the lifespan determinant p66(Shc) improves performance in a spatial memory task, decreases levels of oxidative stress markers in the hippocampus and increases levels of the neurotrophin BDNF in adult mice.* Exp Gerontol. 2008 Mar;43(3):200-8.
 137. Fanelli M, Caprodossi S, Ricci-Vitiani L, Porcellini A, Tomassoni-Ardori F, Amatori S, Andreoni F, Magnani M, De Maria R, Santoni A, Minucci S, **Pelicci PG**. *Loss of pericentromeric DNA methylation pattern in human glioblastoma is associated with altered DNA methyltransferases expression and involves the stem cell compartment.* Oncogene. 2008 Jan 10;27(3):358-65.
 138. Gorello P, La Starza R, Brandimarte L, Trisolini SM, Pierini V, Crescenzi B, Limongi MZ, Nanni M, Belloni E, Tapinassi C, Gerbino E, Martelli MF, Foà R, Meloni G, **Pelicci PG**, Mecucci C. *A PDGFRB-positive acute myeloid malignancy with a new t(5;12)(q33;p13.3) involving the ERC1 gene.* Leukemia. 2008 Jan;22(1):216-8.
-
- 2007
139. Shing DC, Trubia M, Marchesi F, Radaelli E, Belloni E, Tapinassi C, Scanziani E, Mecucci C, Crescenzi B, Lahortiga I, Odero MD, Zardo G, Gruszka A, Minucci S, Di Fiore PP, **Pelicci PG**. *Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice.* J Clin Invest. 2007 Dec;117(12):3696-707.
 140. Zaccagnini G, Martelli F, Magenta A, Cencioni C, Fasanaro P, Nicoletti C, Biglioli P, **Pelicci PG**, Capogrossi MC. *p66(ShcA) and oxidative stress modulate myogenic differentiation and skeletal muscle regeneration after hind limb ischemia.* J Biol Chem. 2007 Oct 26;282(43):31453-9.
 141. Patrussi L, Ulivieri C, Lucherini OM, Paccani SR, Gamberucci A, Lanfranccone L, **Pelicci PG**, Baldari CT. *p52Shc is required for CXCR4-dependent signaling and chemotaxis in T cells.* Blood. 2007 Sep 15;110(6):1730-8.
 142. Menini S, Iacobini C, Ricci C, Oddi G, Pesce C, Pugliese F, Block K, Abboud HE, Giorgio M, Migliaccio E, **Pelicci PG**, Pugliese G. *Ablation of the gene encoding p66Shc protects mice against AGE-induced glomerulopathy by preventing oxidant-dependent tissue injury and further AGE accumulation.* Diabetologia. 2007 Sep;50(9):1997-2007.
 143. Giorgio M, Trinei M, Migliaccio E, **Pelicci PG**. *Hydrogen peroxide: a metabolic by-product or a common mediator of ageing signals?* Nat Rev Mol Cell Biol. 2007 Sep;8(9):722-8. Review.
 144. Minucci S, **Pelicci PG**. *Determinants of oncogenic transformation in acute promyelocytic leukemia: the hetero-union makes the force.* Cancer Cell. 2007 Jul;12(1):1-3. Review.
 145. Villa R, Pasini D, Gutierrez A, Morey L, Occhionorelli M, Viré E, Nomdedeu JF, Jenuwein T, **Pelicci PG**, Minucci S, Fuks F, Helin K, Di Croce L. *Role of the polycomb repressive complex 2 in acute promyelocytic leukemia.* Cancer Cell. 2007 Jun;11(6):513-25.
 146. Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia. Fazi F, Zardo G, Gelmetti V, Travaglini L, Ciolfi A, Di Croce L, Rosa A, Bozzoni I, Grignani F, Lo-Coco F, **Pelicci PG**, Nervi C. Blood. 2007 May 15;109(10):4432-40.

147. Carraro F, Pucci A, Pellegrini M, **Pelicci PG**, Baldari CT, Naldini A. *p66Shc is involved in promoting HIF-1 α accumulation and cell death in hypoxic T cells.* J Cell Physiol. 2007 May;211(2):439-47.
148. Zanardi A, Giorgetti L, Botrugno OA, Minucci S, Milani P, **Pelicci PG**, Carbone R. *Immunocell-array for molecular dissection of multiple signaling pathways in mammalian cells.* Mol Cell Proteomics. 2007 May;6(5):939-47.
149. Franceschi C, Bezrukov V, Blanché H, Bolund L, Christensen K, de Benedictis G, Deiana L, Gonos E, Hervonen A, Yang H, Jeune B, Kirkwood TB, Kristensen P, Leon A, **Pelicci PG**, Peltonen L, Poulain M, Rea IM, Remacle J, Robine JM, Schreiber S, Sikora E, Slagboom PE, Spazzafumo L, Stazi MA, Toussaint O, Vaupel JW. *Genetics of healthy aging in Europe: the EU-integrated project GEHA (Genetics of Healthy Aging).* Ann N Y Acad Sci. 2007 Apr;1100:21-45. Review.
150. Carbone R, Giorgetti L, Zanardi A, Marangi I, Chierici E, Bongiorno G, Fiorentini F, Faretta M, Piseri P, **Pelicci PG**, Milani P. *Retroviral microarray-based platform on nanostructured TiO₂ for functional genomics and drug discovery.* Biomaterials. 2007 Apr;28(13):2244-53.
151. Marinelli A, Bossi D, **Pelicci PG**, Minucci S. *A redundant oncogenic potential of the retinoic receptor (RAR) α , β and γ isoforms in acute promyelocytic leukemia.* Leukemia. 2007 Apr;21(4):647-50.
152. Pinton P, Rimessi A, Marchi S, Orsini F, Migliaccio E, Giorgio M, Contursi C, Minucci S, Mantovani F, Wieckowski MR, Del Sal G, **Pelicci PG**, Rizzuto R. *Protein kinase C β and prolyl isomerase 1 regulate mitochondrial effects of the life-span determinant p66Shc.* Science. 2007 Feb 2;315(5812):659-63.
153. Pellegrini M, Finetti F, Petronilli V, Ulivieri C, Giusti F, Lupetti P, Giorgio M, **Pelicci PG**, Bernardi P, Baldari CT. *p66SHC promotes T cell apoptosis by inducing mitochondrial dysfunction and impaired Ca²⁺ homeostasis.* Cell Death Differ. 2007 Feb;14(2):338-47.
154. Berry A, Capone F, Giorgio M, **Pelicci PG**, de Kloet ER, Alleva E, Minghetti L, Cirulli F. *Deletion of the life span determinant p66Shc prevents age-dependent increases in emotionality and pain sensitivity in mice.* Exp Gerontol. 2007 Jan-Feb;42(1-2):37-45.

2006

155. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, Schurra C, Garre' M, Nuciforo PG, Bensimon A, Maestro R, **Pelicci PG**, d'Adda di Fagagna F. *Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication.* Nature. 2006 Nov 30;444(7119):638-42.
156. Falini B, Martelli MP, Bolli N, Bonasso R, Ghia E, Pallotta MT, Diverio D, Nicoletti I, Pacini R, Tabarrini A, Galletti BV, Mannucci R, Roti G, Rosati R, Specchia G, Liso A, Tiacci E, Alcalay M, Luzi L, Volorio S, Bernard L, Guarini A, Amadori S, Mandelli F, Pane F, Lo-Coco F, Saglio G, **Pelicci PG**, Martelli MF, Mecucci C. *Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia.* Blood. 2006 Sep 15;108(6):1999-2005.
157. Cimino G, Lo-Coco F, Fenu S, Travaglini L, Finolezzi E, Mancini M, Nanni M, Careddu A, Fazi F, Padula F, Fiorini R, Spiriti MA, Petti MC, Venditti A, Amadori S, Mandelli F, **Pelicci PG**, Nervi C. *Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia.* Cancer Res. 2006 Sep 1;66(17):8903-11.
158. Marchesi F, Minucci S, **Pelicci PG**, Gobbi A, Scanziani E. *Immunohistochemical detection of Ym1/Ym2 chitinase-like lectins associated with hyalinosis and polypoid adenomas of the transitional epithelium in a mouse with acute myeloid leukemia.* Vet Pathol. 2006 Sep;43(5):773-6.
159. Mariano AR, Colombo E, Luzi L, Martinelli P, Volorio S, Bernard L, Meani N, Bergomas R, Alcalay M, **Pelicci PG**. *Cytoplasmic localization of NPM in myeloid leukemias is dictated by gain-of-function mutations that create a functional nuclear export signal.* Oncogene. 2006 Jul 20;25(31):4376-80.
160. Rota M, LeCapitaine N, Hosoda T, Boni A, De Angelis A, Padin-Iruegas ME, Esposito G, Vitale S, Urbanek K, Casarsa C, Giorgio M, Lüscher TF, **Pelicci PG**, Anversa P, Leri A, Kajstura J. *Diabetes promotes cardiac stem cell aging and heart failure, which are prevented by deletion of the p66shc gene.* Circ Res. 2006 Jul 7;99(1):42-52.
161. Carbone R, Marangi I, Zanardi A, Giorgetti L, Chierici E, Berlanda G, Podestà A, Fiorentini F, Bongiorno G, Piseri P, **Pelicci PG**, Milani P. *Biocompatibility of cluster-assembled nanostructured TiO₂ with primary and cancer cells.* Biomaterials. 2006 Jun;27(17):3221-9.
162. Trinei M, Berniakovich I, **Pelicci PG**, Giorgio M. *Mitochondrial DNA copy number is regulated by cellular proliferation: a role for Ras and p66(Shc).* Biochim Biophys Acta. 2006 May-Jun;1757(5-6):624-30.
163. Colombo E, Martinelli P, Zamponi R, Shing DC, Bonetti P, Luzi L, Volorio S, Bernard L, Prunerì G, Alcalay M, **Pelicci PG**. *Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant.* Cancer Res. 2006 Mar 15;66(6):3044-50.

164. Migliaccio E, Giorgio M, **Pelicci PG**. *Apoptosis and aging: role of p66Shc redox protein*. Antioxid Redox Signal. 2006 Mar-Apr;8(3-4):600-8. Review.
165. Falini B, Bigerna B, Pucciarini A, Tiacci E, Mecucci C, Morris SW, Bolli N, Rosati R, Hanissian S, Ma Z, Sun Y, Colombo E, Arber DA, Pacini R, La Starza R, Verducci Galletti B, Liso A, Martelli MP, Diverio D, **Pelicci PG**, Lo Coco F, Martelli MF. *Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): a comparison with NPMc+ AML*. Leukemia. 2006 Feb;20(2):368-71.
166. Carbone R, Botrugno OA, Ronzoni S, Insinga A, Di Croce L, **Pelicci PG**, Minucci S. *Recruitment of the histone methyltransferase SUV39H1 and its role in the oncogenic properties of the leukemia-associated PML-retinoic acid receptor fusion protein*. Mol Cell Biol. 2006 Feb;26(4):1288-96.
167. Villa R, Morey L, Raker VA, Buschbeck M, Gutierrez A, De Santis F, Corsaro M, Varas F, Bossi D, Minucci S, **Pelicci PG**, Di Croce L. *The methyl-CpG binding protein MBD1 is required for PML-RAR α function*. Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1400-5.
168. Trubia M, Albano F, Cavazzini F, Cambrin GR, Quarta G, Fabbiano F, Ciambelli F, Magro D, Hernandez JM, Mancini M, Diverio D, **Pelicci PG**, Coco FL, Mecucci C, Specchia G, Rocchi M, Liso V, Castoldi G, Cuneo A. *Characterization of a recurrent translocation t(2;3)(p15-22;q26) occurring in acute myeloid leukaemia*. Leukemia. 2006 Jan;20(1):48-54.
169. Minucci S, **Pelicci PG**. *Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer*. Nat Rev Cancer. 2006 Jan;6(1):38-51. Review.

2005

170. Gorletta TA, Gasparini P, D'Elios MM, Trubia M, **Pelicci PG**, Di Fiore PP. *Frequent loss of heterozygosity without loss of genetic material in acute myeloid leukemia with a normal karyotype*. Genes Chromosomes Cancer. 2005 Nov;44(3):334-7.
171. Colombo E, Bonetti P, Lazzerini Denchi E, Martinelli P, Zamponi R, Marine JC, Helin K, Falini B, **Pelicci PG**. *Nucleophosmin is required for DNA integrity and p19Arf protein stability*. Mol Cell Biol. 2005 Oct;25(20):8874-86.
172. Doumont G, Martoriati A, Beekman C, Bogaerts S, Mee PJ, Bureau F, Colombo E, Alcalay M, Bellefroid E, Marchesi F, Scanziani E, **Pelicci PG**, Marine JC. *G1 checkpoint failure and increased tumor susceptibility in mice lacking the novel p53 target Ptpv*. EMBO J. 2005 Sep 7;24(17):3093-103.
173. Alcalay M, Tiacci E, Bergomas R, Bigerna B, Venturini E, Minardi SP, Meani N, Diverio D, Bernard L, Tizzoni L, Volorio S, Luzi L, Colombo E, Lo Coco F, Mecucci C, Falini B, **Pelicci PG**. *Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance*. Blood. 2005 Aug 1;106(3):899-902.
174. Giorgio M, Migliaccio E, Orsini F, Paolucci D, Moroni M, Contursi C, Pelliccia G, Luzi L, Minucci S, Marcaccio M, Pinton P, Rizzuto R, Bernardi P, Paolucci F, **Pelicci PG**. *Electron transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis*. Cell. 2005 Jul 29;122(2):221-33.
175. Pilatrin C, Cilloni D, Messa E, Morotti A, Giugliano E, Pautasso M, Familiari U, Cappia S, **Pelicci PG**, Lo Coco F, Saglio G, Guerrasio A. *Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid*. Cancer. 2005 Jul 1;104(1):101-9.
176. Caprodossi S, Pedinotti M, Amantini C, Santoni G, Minucci S, **Pelicci PG**, Fanelli M. *Differentiation response of acute promyelocytic leukemia cells and PML/RAR α leukemogenic activity studies by real-time RT-PCR*. Mol Biotechnol. 2005 Jul;30(3):231-8.
177. Insinga A, Minucci S, **Pelicci PG**. *Mechanisms of selective anticancer action of histone deacetylase inhibitors*. Cell Cycle. 2005 Jun;4(6):741-3.
178. Meani N, Minardi S, Licciulli S, Gelmetti V, Coco FL, Nervi C, **Pelicci PG**, Müller H, Alcalay M. *Molecular signature of retinoic acid treatment in acute promyelocytic leukemia*. Oncogene. 2005 May 5;24(20):3358-68.
179. Lahortiga I, Vázquez I, Belloni E, Román JP, Gasparini P, Novo FJ, Zudaire I, **Pelicci PG**, Hernández JM, Calasanz MJ, Odero MD. *FISH analysis of hematological neoplasias with 1p36 rearrangements allows the definition of a cluster of 2.5 Mb included in the minimal region deleted in 1p36 deletion syndrome*. Hum Genet. 2005 May;116(6):476-85.
180. Patrussi L, Savino MT, Pellegrini M, Paccani SR, Migliaccio E, Plyte S, Lanfranccone L, **Pelicci PG**, Baldari CT. *Cooperation and selectivity of the two Grb2 binding sites of p52Shc in T-cell antigen receptor signaling to Ras family GTPases and Myc-dependent survival*. Oncogene. 2005 Mar 24;24(13):2218-28.

181. Fazi F, Travaglini L, Carotti D, Palitti F, Diverio D, Alcalay M, McNamara S, Miller WH Jr, Lo Coco F, **Pelicci PG**, Nervi C. *Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo.* Oncogene. 2005 Mar 10;24(11):1820-30.
182. Belloni E, Trubia M, Gasparini P, Micucci C, Tapinassi C, Confalonieri S, Nuciforo P, Martino B, Lo-Coco F, **Pelicci PG**, Di Fiore PP. *8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes* Genes Chromosomes Cancer. 2005 Mar;42(3):320-5.
183. Martoriati A, Doumont G, Alcalay M, Bellefroid E, **Pelicci PG**, Marine JC. *dapk1, encoding an activator of a p19ARF-p53-mediated apoptotic checkpoint, is a transcription target of p53.* Oncogene. 2005 Feb 17;24(8):1461-6.
184. Lunghi P, Tabilio A, Lo-Coco F, **Pelicci PG**, Bonati A. *Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells.* Leukemia. 2005 Feb;19(2):234-44.
185. Kindle KB, Troke PJ, Collins HM, Matsuda S, Bossi D, Bellodi C, Kalkhoven E, Salomoni P, **Pelicci PG**, Minucci S, Heery DM. *MOZ-TIF2 inhibits transcription by nuclear receptors and p53 by impairment of CBP function.* Mol Cell Biol. 2005 Feb;25(3):988-1002.
186. Brenner C, Deplus R, Didelot C, Loriot A, Viré E, De Smet C, Gutierrez A, Danovi D, Bernard D, Boon T, **Pelicci PG**, Amati B, Kouzarides T, de Launoit Y, Di Croce L, Fuks F. *Myc represses transcription through recruitment of DNA methyltransferase corepressor.* EMBO J. 2005 Jan 26;24(2):336-46.
187. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettrossi V, Saglio G, Mandelli F, Lo-Coco F, **Pelicci PG**, Martelli MF; GIMEMA Acute Leukemia Working Party. *Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.* N Engl J Med. 2005 Jan 20;352(3):254-66.
188. Insinga A, **Pelicci PG**, Inucci S. *Leukemia-associated fusion proteins. Multiple mechanisms of action to drive cell transformation.* Cell Cycle. 2005 Jan;4(1):67-9. Review.
189. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S, **Pelicci PG**. *Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway.* Nat Med. 2005 Jan;11(1):71-6.
190. Caprodossi S, Galluzzi L, Biagetti S, Della Chiara G, **Pelicci PG**, Magnani M, Fanelli M. *In vitro inhibition of promyelocytic leukemia/retinoic acid receptor-alpha (PML/RARalpha) expression and leukemogenic activity by DNA/LNA chimeric antisense oligos.* Oncol Res. 2005;16(3):157-66.

2004

191. Francia P, delli Gatti C, Bachschmid M, Martin-Padura I, Savoia C, Migliaccio E, **Pelicci PG**, Schiavoni M, Lüscher TF, Volpe M, Cosentino F. *Deletion of p66shc gene protects against age-related endothelial dysfunction.* Circulation. 2004 Nov 2;110(18):2889-95.
192. Belloni E, Trubia M, Mancini M, Derme V, Nanni M, Lahortiga I, Riccioni R, Confalonieri S, Lo-Coco F, Di Fiore PP, **Pelicci PG**. *A new complex rearrangement involving the ETV6, LOC115548, and MN1 genes in a case of acute myeloid leukemia.* Genes Chromosomes Cancer. 2004 Nov;41(3):272-7.
193. Troglio F, Echart C, Gobbi A, Pawson T, **Pelicci PG**, De Simoni MG, Pelicci G. *The Rai (Shc C) adaptor protein regulates the neuronal stress response and protects against cerebral ischemia.* Proc Natl Acad Sci U S A. 2004 Oct 26;101(43):15476-81.
194. Villa R, De Santis F, Gutierrez A, Minucci S, **Pelicci PG**, Di Croce L. *Epigenetic gene silencing in acute promyelocytic leukemia.* Biochem Pharmacol. 2004 Sep 15;68(6):1247-54. Review.
195. Danovi D, Meulmeester E, Pasini D, Migliorini D, Capra M, Frenk R, de Graaf P, Francoz S, Gasparini P, Gobbi A, Helin K, **Pelicci PG**, Jochemsen AG, Marine JC. *Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity.* Mol Cell Biol. 2004 Jul;24(13):5835-43.
196. Zaccagnini G, Martelli F, Fasanaro P, Magenta A, Gaetano C, Di Carlo A, Biglioli P, Giorgio M, Martin-Padura I, **Pelicci PG**, Capogrossi MC. *p66ShcA modulates tissue response to hindlimb ischemia.* Circulation. 2004 Jun 15;109(23):2917-23.
197. Orsini F, Migliaccio E, Moroni M, Contursi C, Raker VA, Piccini D, Martin-Padura I, Pelliccia G, Trinei M, Bono M, Puri C, Tacchetti C, Ferrini M, Mannucci R, Nicoletti I, Lanfranccone L, Giorgio M, **Pelicci PG**. *The life span determinant p66Shc localizes to mitochondria where it associates with mitochondrial heat shock protein 70 and regulates trans-membrane potential.* J Biol Chem. 2004 Jun 11;279(24):25689-95.
198. Transidico P, Bianchi M, Capra M, **Pelicci PG**, Faretta M. *From cells to tissues: fluorescence confocal microscopy in the study of histological samples.* Microsc Res Tech. 2004 Jun 1;64(2):89-95.
199. Mandalà M, Curigliano G, Bucciarelli P, Ferretti G, Mannucci PM, Colleoni M, Ventura A, Peruzzotti G, Severi G, **Pelicci PG**, Biffi R, Orsi F, Cinieri S, Goldhirsch A. *Factor V Leiden and G20210A prothrombin*

- mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. *Ann Oncol*. 2004 Apr;15(4):590-3.
200. Fanelli M, Fantozzi A, De Luca P, Caprodossi S, Matsuzawa S, Lazar MA, **Pelicci PG**, Minucci S. *The coiled-coil domain is the structural determinant for mammalian homologues of Drosophila Sina-mediated degradation of promyelocytic leukemia protein and other tripartite motif proteins by the proteasome*. *J Biol Chem*. 2004 Feb 13;279(7):5374-9.
 201. Ventura A, Maccarana M, Raker VA, **Pelicci PG**. *A cryptic targeting signal induces isoform-specific localization of p46Shc to mitochondria*. *J Biol Chem*. 2004 Jan 16;279(3):2299-306.
 202. Lahortiga I, Agirre X, Belloni E, Vázquez I, Larrayoz MJ, Gasparini P, Lo Coco F, **Pelicci PG**, Calasanz MJ, Odero MD. *Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells*. *Oncogene*. 2004 Jan 8;23(1):311-6.
 203. **Pelicci PG**. *Do tumor-suppressive mechanisms contribute to organism aging by inducing stem cell senescence?* *J Clin Invest*. 2004 Jan;113(1):4-7. Review.

2003

204. Alcalay M, Meani N, Gelmetti V, Fantozzi A, Fagioli M, Orleth A, Riganelli D, Sebastiani C, Cappelli E, Casciari C, Scurpi MT, Mariano AR, Minardi SP, Luzi L, Muller H, Di Fiore PP, Frosina G, **Pelicci PG**. *Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair*. *J Clin Invest*. 2003 Dec;112(11):1751-61.
205. Segalla S, Rinaldi L, Kilstrup-Nielsen C, Badaracco G, Minucci S, **Pelicci PG**, Landsberger N. *Retinoic acid receptor alpha fusion to PML affects its transcriptional and chromatin-remodeling properties*. *Mol Cell Biol*. 2003 Dec;23(23):8795-808.
206. Lunghi P, Tabilio A, Dall'Aglia PP, Ridolo E, Carlo-Stella C, **Pelicci PG**, Bonati A. *Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts*. *Leukemia*. 2003 Sep;17(9):1783-93.
207. Scherer SW, Cheung J, MacDonald JR, Osborne LR, Nakabayashi K, Herbrick JA, Carson AR, Parker-Katirae L, Skaug J, Khaja R, Zhang J, Hudek AK, Li M, Haddad M, Duggan GE, Fernandez BA, Kanematsu E, Gentles S, Christopoulos CC, Choufani S, Kwasnicka D, Zheng XH, Lai Z, Nusskern D, Zhang Q, Gu Z, Lu F, Zeeman S, Nowaczyk MJ, Teshima I, Chitayat D, Shuman C, Weksberg R, Zackai EH, Grebe TA, Cox SR, Kirkpatrick SJ, Rahman N, Friedman JM, Heng HH, **Pelicci PG**, Lo-Coco F, Belloni E, Shaffer LG, Pober B, Morton CC, Gusella JF, Bruns GA, Korf BR, Quade BJ, Ligon AH, Ferguson H, Higgins AW, Leach NT, Herrick SR, Lemyre E, Farra CG, Kim HG, Summers AM, Gripp KW, Roberts W, Szatmari P, Winsor EJ, Grzeschik KH, Teebi A, Minassian BA, Kere J, Armengol L, Pujana MA, Estivill X, Wilson MD, Koop BF, Tosi S, Moore GE, Boright AP, Zlotorynski E, Kerem B, Kroisel PM, Petek E, Oscier DG, Mould SJ, Döhner H, Döhner K, Rommens JM, Vincent JB, Venter JC, Li PW, Mural RJ, Adams MD, Tsui LC. *Human chromosome 7: DNA sequence and biology*. *Science*. 2003 May 2;300(5620):767-72.
208. Bruno S, Ghiotto F, Fais F, Fagioli M, Luzi L, **Pelicci PG**, Grossi CE, Ciccone E. *The PML gene is not involved in the regulation of MHC class I expression in human cell lines*. *Blood*. 2003 May 1;101(9):3514-9.
209. Masseroli M, Cerveri P, **Pelicci PG**, Alcalay M. *GAAS: gene array analyzer software for management, analysis and visualization of gene expression data*. *Bioinformatics*. 2003 Apr 12;19(6):774-5.
210. La Starza R, Trubia M, Crescenzi B, Matteucci C, Negrini M, Martelli MF, **Pelicci PG**, Mecucci C. *Human homeobox gene HOXC13 is the partner of NUP98 in adult acute myeloid leukemia with t(11;12)(p15;q13)*. *Genes Chromosomes Cancer*. 2003 Apr;36(4):420-3.
211. Di Croce L, **Pelicci PG**. *Tumour-associated hypermethylation: silencing E-cadherin expression enhances invasion and metastasis*. *Eur J Cancer*. 2003 Mar;39(4):413-4.
212. Marchesi F, Monestiroli SV, Capillo M, Gobbi A, Minucci S, **Pelicci PG**, Scanziani E. *Eosinophilic crystals as a distinctive morphologic feature of a hyaline droplet nephropathy in a mouse model of acute myelogenous leukaemia*. *J Vet Med A Physiol Pathol Clin Med*. 2003 Mar;50(2):103-7.

2002

213. Puccetti E, Obradovic D, Beissert T, Bianchini A, Washburn B, Chiaradonna F, Boehrer S, Hoelzer D, Ottmann OG, **Pelicci PG**, Nervi C, Ruthardt M. *AML-associated translocation products block vitamin D(3)-induced differentiation by sequestering the vitamin D(3) receptor*. *Cancer Res*. 2002 Dec 1;62(23):7050-8.
214. Ventura A, **Pelicci PG**. *Semaphorins: green light for redox signaling?* *Sci STKE*. 2002 Oct 22;2002(155):pe44. Review.

215. Minucci S, Monestiroli S, Giavara S, Ronzoni S, Marchesi F, Insinga A, Diverio D, Gasparini P, Capillo M, Colombo E, Matteucci C, Contegno F, Lo-Coco F, Scanziani E, Gobbi A, **Pelicci PG**. *PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors*. Blood. 2002 Oct 15;100(8):2989-95.
216. Pelicci G, Troglio F, Bodini A, Melillo RM, Pettirossi V, Coda L, De Giuseppe A, Santoro M, **Pelicci PG**. *The neuron-specific Rai (ShcC) adaptor protein inhibits apoptosis by coupling Ret to the phosphatidylinositol 3-kinase/Akt signaling pathway*. Mol Cell Biol. 2002 Oct;22(20):7351-63.
217. Petti MC, Fazi F, Gentile M, Diverio D, De Fabritiis P, De Propriis MS, Fiorini R, Spiriti MA, Padula F, **Pelicci PG**, Nervi C, Lo Coco F. *Complete remission through blast cell differentiation in PLZF/RARalpha-positive acute promyelocytic leukemia: in vitro and in vivo studies*. Blood. 2002 Aug 1;100(3):1065-7.
218. La Starza R, Trubia M, Testoni N, Ottaviani E, Belloni E, Crescenzi B, Martelli M, Flandrin G, **Pelicci PG**, Mecucci C. *Clonal eosinophils are a morphologic hallmark of ETV6/ABL1 positive acute myeloid leukemia*. Haematologica. 2002 Aug;87(8):789-94.
219. Migliorini D, Lazzerini Denchi E, Danovi D, Jochemsen A, Capillo M, Gobbi A, Helin K, **Pelicci PG**, Marine JC. *Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development*. Mol Cell Biol. 2002 Aug;22(15):5527-38.
220. Bischof O, Kirsh O, Pearson M, Itahana K, **Pelicci PG**, Dejean A. *Deconstructing PML-induced premature senescence*. EMBO J. 2002 Jul 1;21(13):3358-69.
221. Colombo E, Marine JC, Danovi D, Falini B, **Pelicci PG**. *Nucleophosmin regulates the stability and transcriptional activity of p53*. Nat Cell Biol. 2002 Jul;4(7):529-33.
222. **Pelicci PG**. *A new class of anti-cancer drugs: HDAC-inhibitors*. Suppl Tumori. 2002 Jul-Aug;1(4):S66. Review.
223. Ventura A, Luzi L, Pacini S, Baldari CT, **Pelicci PG**. *The p66Shc longevity gene is silenced through epigenetic modifications of an alternative promoter*. J Biol Chem. 2002 Jun 21;277(25):22370-6.
224. Trinei M, Giorgio M, Cicalese A, Barozzi S, Ventura A, Migliaccio E, Milia E, Padura IM, Raker VA, Maccarana M, Petronilli V, Minucci S, Bernardi P, Lanfrancone L, **Pelicci PG**. *A p53-p66Shc signalling pathway controls intracellular redox status, levels of oxidation-damaged DNA and oxidative stress-induced apoptosis*. Oncogene. 2002 May 30;21(24):3872-8.
225. Langley E, Pearson M, Faretta M, Bauer UM, Frye RA, Minucci S, **Pelicci PG**, Kouzarides T. *Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence*. EMBO J. 2002 May 15;21(10):2383-96.
226. Tarr PE, Roncarati R, Pelicci G, **Pelicci PG**, D'Adamio L. *Tyrosine phosphorylation of the beta-amyloid precursor protein cytoplasmic tail promotes interaction with Shc*. J Biol Chem. 2002 May 10;277(19):16798-804.
227. Carbone R, Pearson M, Minucci S, **Pelicci PG**. *PML NBs associate with the hMre11 complex and p53 at sites of irradiation induced DNA damage*. Oncogene. 2002 Mar 7;21(11):1633-40.
228. Migliorini D, Danovi D, Colombo E, Carbone R, **Pelicci PG**, Marine JC. *Hdmx recruitment into the nucleus by Hdm2 is essential for its ability to regulate p53 stability and transactivation*. J Biol Chem. 2002 Mar 1;277(9):7318-23.
229. Contegno F, Cioce M, **Pelicci PG**, Minucci S. *Targeting protein inactivation through an oligomerization chain reaction*. Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1865-9.
230. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, Faretta M, Fuks F, Lo Coco F, Kouzarides T, Nervi C, Minucci S, **Pelicci PG**. *Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor*. Science. 2002 Feb 8;295(5557):1079-82.

2001

231. Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, **Pelicci PG**, Heinzel T. *Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells*. EMBO J. 2001 Dec 17;20(24):6969-78.
232. **Pelicci PG**. *Inhibitors of histone-deacetylases*. Tumori. 2001 Nov-Dec;87(6):S12-4. Review.
233. Pearson M, **Pelicci PG**. *PML interaction with p53 and its role in apoptosis and replicative senescence*. Oncogene. 2001 Oct 29;20(49):7250-6. Review.
234. Alcalay M, Orleth A, Sebastiani C, Meani N, Chiaradonna F, Casciari C, Sciarpi MT, Gelmetti V, Riganelli D, Minucci S, Fagioli M, **Pelicci PG**. *Common themes in the pathogenesis of acute myeloid leukemia*. Oncogene. 2001 Sep 10;20(40):5680-94. Review.
235. Malabarba MG, Milia E, Faretta M, Zamponi R, **Pelicci PG**, Di Fiore PP. *A repertoire library that allows the selection of synthetic SH2s with altered binding specificities*. Oncogene. 2001 Aug 23;20(37):5186-94.

236. Salcini AE, Hilliard MA, Croce A, Arbucci S, Luzzi P, Tacchetti C, Daniell L, De Camilli P, **Pelicci PG**, Di Fiore PP, Bazzicalupo P. *The Eps15 C. elegans homologue EHS-1 is implicated in synaptic vesicle recycling.* Nat Cell Biol. 2001 Aug;3(8):755-60.
237. Minucci S, Nervi C, Lo Coco F, **Pelicci PG**. *Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?* Oncogene. 2001 May 28;20(24):3110-5. Review.
238. Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzzi L, Riganelli D, Zanaria E, Messali S, Cainarca S, Guffanti A, Minucci S, **Pelicci PG**, Ballabio A. *The tripartite motif family identifies cell compartments.* EMBO J. 2001 May 1;20(9):2140-51.
239. Nervi C, Borello U, Fazi F, Buffa V, **Pelicci PG**, Cossu G. *Inhibition of histone deacetylase activity by trichostatin A modulates gene expression during mouse embryogenesis without apparent toxicity.* Cancer Res. 2001 Feb 15;61(4):1247-9.
240. Ferrara FF, Fazi F, Bianchini A, Padula F, Gelmetti V, Minucci S, Mancini M, **Pelicci PG**, Lo Coco F, Nervi C. *Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia.* Cancer Res. 2001 Jan 1;61(1):2-7.
241. Lunghi P, Tabilio A, Pinelli S, Valmadre G, Ridolo E, Albertini R, Carlo-Stella C, Dall'Aglia PP, **Pelicci PG**, Bonati A. *Expression and activation of SHC/MAP kinase pathway in primary acute myeloid leukemia blasts.* Hematol J. 2001;2(2):70-80.
242. Zhang J, Hug BA, Huang EY, Chen CW, Gelmetti V, Maccarana M, Minucci S, **Pelicci PG**, Lazar MA. *Oligomerization of ETO is obligatory for corepressor interaction.* Mol Cell Biol. 2001 Jan;21(1):156-63.
243. Faretta M, Di Croce L, **Pelicci PG**. *Effects of the acute myeloid leukemia-associated fusion proteins on nuclear architecture.* Semin Hematol. 2001 Jan;38(1):42-53. Review.

2000

244. Santolini E, Puri C, Salcini AE, Gagliani MC, **Pelicci PG**, Tacchetti C, Di Fiore PP. *Numb is an endocytic protein.* J Cell Biol. 2000 Dec 11;151(6):1345-52.
245. Luzzi L, Confalonieri S, Di Fiore PP, **Pelicci PG**. *Evolution of Shc functions from nematode to human.* Curr Opin Genet Dev. 2000 Dec;10(6):668-74. Review.
246. Vannucchi S, Percario ZA, Chiantore MV, Matarrese P, Chelbi-Alix MK, Fagioli M, **Pelicci PG**, Malorni W, Fiorucci G, Romeo G, Affabris E. *Interferon-beta induces S phase slowing via up-regulated expression of PML in squamous carcinoma cells.* Oncogene. 2000 Oct 19;19(44):5041-53.
247. Di Florio S, Sebastiani C, Fagioli M, Di Ianni M, Alfonsi D, Venditti G, **Pelicci PG**, Tabilio A. *Retrovirus-mediated transfer of the herpes simplex virus thymidine kinase and enhanced green fluorescence protein genes in primary T lymphocytes.* Br J Haematol. 2000 Sep;110(4):903-6.
248. Grignani F, Valtieri M, Gabbianelli M, Gelmetti V, Botta R, Luchetti L, Masella B, Morsilli O, Pelosi E, Samoggia P, **Pelicci PG**, Peschle C. *PML/RAR alpha fusion protein expression in normal human hematopoietic progenitors dictates myeloid commitment and the promyelocytic phenotype.* Blood. 2000 Aug 15;96(4):1531-7.
249. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, Higashimoto Y, Appella E, Minucci S, Pandolfi PP, **Pelicci PG**. *PML regulates p53 acetylation and premature senescence induced by oncogenic Ras.* Nature. 2000 Jul 13;406(6792):207-10.
250. Minucci S, Maccarana M, Cioce M, De Luca P, Gelmetti V, Segalla S, Di Croce L, Giavara S, Matteucci C, Gobbi A, Bianchini A, Colombo E, Schiavoni I, Badaracco G, Hu X, Lazar MA, Landsberger N, Nervi C, **Pelicci PG**. *Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation.* Mol Cell. 2000 May;5(5):811-20.
251. Trinei M, Lanfrancone L, Campo E, Pulford K, Mason DY, **Pelicci PG**, Falini B. *A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma.* Cancer Res. 2000 Feb 15;60(4):793-8.
252. Bonati A, Carlo-Stella C, Lunghi P, Albertini R, Pinelli S, Migliaccio E, Sammarelli G, Savoldo B, Tabilio A, Dall'Aglia PP, **Pelicci PG**. *Selective expression and constitutive phosphorylation of SHC proteins in the CD34+ fraction of chronic myelogenous leukemias.* Cancer Res. 2000 Feb 1;60(3):728-32.

1999

253. Doria M, Salcini AE, Colombo E, Parslow TG, **Pelicci PG**, Di Fiore PP. *The eps15 homology (EH) domain-based interaction between eps15 and hrb connects the molecular machinery of endocytosis to that of nucleocytoplasmic transport.* J Cell Biol. 1999 Dec 27;147(7):1379-84.
254. Pollock JL, Westervelt P, Kurichety AK, **Pelicci PG**, Grisolan JL, Ley TJ. *A bcr-3 isoform of RARalpha-PML potentiates the development of PML-RARalpha-driven acute promyelocytic leukemia.* Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15103-8.

255. Migliaccio E, Giorgio M, Mele S, Pelicci G, Reboldi P, Pandolfi PP, Lanfranccone L, **Pelicci PG**. *The p66shc adaptor protein controls oxidative stress response and life span in mammals*. Nature. 1999 Nov 18;402(6759):309-13.
 256. Falini B, Pulford K, Pucciarini A, Carbone A, De Wolf-Peeters C, Cordell J, Fizzotti M, Santucci A, **Pelicci PG**, Pileri S, Campo E, Ott G, Delsol G, Mason DY. *Lymphomas expressing ALK fusion protein(s) other than NPM-ALK*. Blood. 1999 Nov 15;94(10):3509-15.
 257. Grignani F, Gelmetti V, Fanelli M, Rogaia D, De Matteis S, Ferrara FF, Bonci D, Grignani F, Nervi C, **Pelicci PG**. *Formation of PML/RAR alpha high molecular weight nuclear complexes through the PML coiled-coil region is essential for the PML/RAR alpha-mediated retinoic acid response*. Oncogene. 1999 Nov 4;18(46):6313-21.
 258. Lo Coco F, Diverio D, Falini B, Biondi A, Nervi C, **Pelicci PG**. *Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia*. Blood. 1999 Jul 1;94(1):12-22. Review.
 259. Minucci S, Cioce M, Maccarana M, **Pelicci PG**. *The APL-associated fusion proteins*. Haematologica. 1999 Jun;84 Suppl EHA-4:70-1. Review.
 260. Mozziconacci MJ, Liberatore C, Grignani F, Sainty D, **Pelicci PG**, Birg F, Lafage-Pochitaloff M. *Atypical response to all-trans retinoic acid in a der(5)t(5;17) acute promyelocytic leukemia*. Leukemia. 1999 Jun;13(6):862-8.
 261. Casini T, **Pelicci PG**. *A function of p21 during promyelocytic leukemia cell differentiation independent of CDK inhibition and cell cycle arrest*. Oncogene. 1999 May 27;18(21):3235-43.
 262. Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peters C, Verhoef G, Menestrina F, Todeschini G, Paulli M, Lazzarino M, Giardini R, Aiello A, Foss HD, Araujo I, Fizzotti M, **Pelicci PG**, Flenghi L, Martelli MF, Santucci A. *ALK+ lymphoma: clinico-pathological findings and outcome*. Blood. 1999 Apr 15;93(8):2697-706.
 263. Minucci S, **Pelicci PG**. *Retinoid receptors in health and disease: co-regulators and the chromatin connection*. Semin Cell Dev Biol. 1999 Apr;10(2):215-25. Review.
 264. Fanelli M, Minucci S, Gelmetti V, Nervi C, Gambacorti-Passerini C, **Pelicci PG**. *Constitutive degradation of PML/RARalpha through the proteasome pathway mediates retinoic acid resistance*. Blood. 1999 Mar 1;93(5):1477-81.
 265. Gottifredi V, Pelicci G, Munarriz E, Maione R, **Pelicci PG**, Amati P. *Polyomavirus large T antigen induces alterations in cytoplasmic signalling pathways involving Shc activation*. J Virol. 1999 Feb;73(2):1427-37.
 266. Torrisi MR, Lotti LV, Belleudi F, Gradini R, Salcini AE, Confalonieri S, **Pelicci PG**, Di Fiore PP. *Eps15 is recruited to the plasma membrane upon epidermal growth factor receptor activation and localizes to components of the endocytic pathway during receptor internalization*. Mol Biol Cell. 1999 Feb;10(2):417-34.
 267. Cordell JL, Pulford KA, Bigerna B, Roncador G, Banham A, Colombo E, **Pelicci PG**, Mason DY, Falini B. *Detection of normal and chimeric nucleophosmin in human cells*. Blood. 1999 Jan 15;93(2):632-42.
-
- 1998
268. Gelmetti V, Zhang J, Fanelli M, Minucci S, **Pelicci PG**, Lazar MA. *Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO*. Mol Cell Biol. 1998 Dec;18(12):7185-91.
 269. Paoluzi S, Castagnoli L, Lauro I, Salcini AE, Coda L, Fre' S, Confalonieri S, **Pelicci PG**, Di Fiore PP, Cesareni G. *Recognition specificity of individual EH domains of mammals and yeast*. EMBO J. 1998 Nov 16;17(22):6541-50.
 270. Cattaneo E, **Pelicci PG**. *Emerging roles for SH2/PTB-containing Shc adaptor proteins in the developing mammalian brain*. Trends Neurosci. 1998 Nov;21(11):476-81. Review.
 271. Nervi C, Ferrara FF, Fanelli M, Rippo MR, Tomassini B, Ferrucci PF, Ruthardt M, Gelmetti V, Gambacorti-Passerini C, Diverio D, Grignani F, **Pelicci PG**, Testi R. *Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein*. Blood. 1998 Oct 1;92(7):2244-51.
 272. Falini B, Bigerna B, Fizzotti M, Pulford K, Pileri SA, Delsol G, Carbone A, Paulli M, Magrini U, Menestrina F, Giardini R, Pilotti S, Mezzelani A, Ugolini B, Billi M, Pucciarini A, Pacini R, **Pelicci PG**, Flenghi L. *ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum*. Am J Pathol. 1998 Sep;153(3):875-86.
 273. Pacini S, Olivieri C, Di Somma MM, Isacchi A, Lanfranccone L, **Pelicci PG**, Telford JL, Baldari CT. *Tyrosine 474 of ZAP-70 is required for association with the Shc adaptor and for T-cell antigen receptor-dependent gene activation*. J Biol Chem. 1998 Aug 7;273(32):20487-93.

274. Diverio D, Rossi V, Avvisati G, De Santis S, Pistilli A, Pane F, Saglio G, Martinelli G, Petti MC, Santoro A, **Pelicci PG**, Mandelli F, Biondi A, Lo Coco F. *Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial.* Blood. 1998 Aug 1;92(3):784-9.
275. Mozziconacci MJ, Liberatore C, Brunel V, Grignani F, Arnoulet C, Ferrucci PF, Fernandez F, Sainty D, **Pelicci PG**, Birg F, Lafage-Pochitaloff M. *In vitro response to all-trans retinoic acid of acute promyelocytic leukemias with nonreciprocal PML/RARA or RARA/PML fusion genes.* Genes Chromosomes Cancer. 1998 Jul;22(3):241-50.
276. Fagioli M, Alcalay M, Tomassoni L, Ferrucci PF, Mencarelli A, Riganelli D, Grignani F, Pozzan T, Nicoletti I, Grignani F, **Pelicci PG**. *Cooperation between the RING + B1-B2 and coiled-coil domains of PML is necessary for its effects on cell survival.* Oncogene. 1998 Jun 4;16(22):2905-13.
277. Testa U, Grignani F, Samoggia P, Zanetti C, Riccioni R, Lo Coco F, Diverio D, Felli N, Passerini CG, Grell M, **Pelicci PG**, Peschle C. *The PML/RARalpha fusion protein inhibits tumor necrosis factor-alpha-induced apoptosis in U937 cells and acute promyelocytic leukemia blasts.* J Clin Invest. 1998 May 15;101(10):2278-89.
278. Ruthardt M, Orleth A, Tomassoni L, Puccetti E, Riganelli D, Alcalay M, Mannucci R, Nicoletti I, Grignani F, Fagioli M, **Pelicci PG**. *The acute promyelocytic leukaemia specific PML and PLZF proteins localize to adjacent and functionally distinct nuclear bodies.* Oncogene. 1998 Apr 16;16(15):1945-53.
279. Testa U, Grignani F, Hassan HJ, Rogaia D, Masciulli R, Gelmetti V, Guerriero R, Macioce G, Liberatore C, Barberi T, Mariani G, **Pelicci PG**, Peschle C. *Terminal megakaryocytic differentiation of TF-1 cells is induced by phorbol esters and thrombopoietin and is blocked by expression of PML/RARalpha fusion protein.* Leukemia. 1998 Apr;12(4):563-70.
280. Russo D, Regazzi M, Sacchi S, Visani G, Lazzarino M, Avvisati G, **Pelicci PG**, Dastoli G, Grandi C, Iacona I, Candoni A, Grattoni R, Galieni P, Rupoli S, Liberati AM, Maiolo AT. *All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase.* Leukemia. 1998 Apr;12(4):449-54.
281. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Grignani F, Lazar MA, Minucci S, **Pelicci PG**. *Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia.* Nature. 1998 Feb 19;391(6669):815-8.
282. Alcalay M, Tomassoni L, Colombo E, Stoldt S, Grignani F, Fagioli M, Szekeley L, Helin K, **Pelicci PG**. *The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein.* Mol Cell Biol. 1998 Feb;18(2):1084-93.
283. Coda L, Salcini AE, Confalonieri S, Pelicci G, Sorkina T, Sorkin A, **Pelicci PG**, Di Fiore PP. *Eps15R is a tyrosine kinase substrate with characteristics of a docking protein possibly involved in coated pits-mediated internalization.* J Biol Chem. 1998 Jan 30;273(5):3003-12.
284. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, Lamph WW, Waxman S, **Pelicci PG**, Lo Coco F, Avvisati G, Testa U, Peschle C, Gambacorti-Passerini C, Nervi C, Miller WH Jr. *Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.* Natl Cancer Inst. 1998 Jan 21;90(2):124-33.
285. Grignani F, Kinsella T, Mencarelli A, Valtieri M, Riganelli D, Grignani F, Lanfrancone L, Peschle C, Nolan GP, **Pelicci PG**. *High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein.* Cancer Res. 1998 Jan 1;58(1):14-9.
286. Regazzi MB, Russo D, Iacona I, Sacchi S, Visani G, Lazzarino M, Avvisati G, **Pelicci PG**, Dastoli G, Grandi C, Spreafico S, Grattoni R, Galieni P, Rupoli S, Maiolo AM, Guerra E, Liberati AM. *Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling: 1 Week On/1 Week Off.* Clin Drug Investig. 1998;16(1):25-33.

1997

287. Carbone R, Fré S, Iannolo G, Belleudi F, Mancini P, **Pelicci PG**, Torrisi MR, Di Fiore PP. *eps15 and eps15R are essential components of the endocytic pathway.* Cancer Res. 1997 Dec 15;57(24):5498-504.
288. Falini B, Flenghi L, Fagioli M, Lo Coco F, Cordone I, Diverio D, Pasqualucci L, Biondi A, Riganelli D, Orleth A, Liso A, Martelli MF, **Pelicci PG**, Pileri S. *Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML).* Blood. 1997 Nov 15;90(10):4046-53.
289. Di Fiore PP, **Pelicci PG**, Sorkin A. *EH: a novel protein-protein interaction domain potentially involved in intracellular sorting.* Trends Biochem Sci. 1997 Nov;22(11):411-3. Review.

290. Ferrucci PF, Grignani F, Pearson M, Fagioli M, Nicoletti I, **Pelicci PG**. *Cell death induction by the acute promyelocytic leukemia-specific PML/RARalpha fusion protein*. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10901-6.
 291. Salcini AE, Confalonieri S, Doria M, Santolini E, Tassi E, Minenkova O, Cesareni G, **Pelicci PG**, Di Fiore PP. *Binding specificity and in vivo targets of the EH domain, a novel protein-protein interaction module*. Genes Dev. 1997 Sep 1;11(17):2239-49.
 292. Benedetti L, Levin AA, Scicchitano BM, Grignani F, Allenby G, Diverio D, Lo Coco F, Avvisati G, Ruthardt M, Adamo S, **Pelicci PG**, Nervi C. *Characterization of the retinoid binding properties of the major fusion products present in acute promyelocytic leukemia cells*. Blood. 1997 Aug 1;90(3):1175-85.
 293. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, Broccia G, Cerri R, Falda M, Fioritoni G, Leoni F, Liso V, Petti MC, Rodeghiero F, Saglio G, Vegna ML, Visani G, Jehn U, Willemze R, Muus P, **Pelicci PG**, Biondi A, Lo Coco F. *Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy*. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood. 1997 Aug 1;90(3):1014-21.
 294. Ruthardt M, Testa U, Nervi C, Ferrucci PF, Grignani F, Puccetti E, Grignani F, Peschle C, **Pelicci PG**. *Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins on retinoic acid signalling*. Mol Cell Biol. 1997 Aug;17(8):4859-69.
 295. Dente L, Vetriani C, Zucconi A, Pelicci G, Lanfrancone L, **Pelicci PG**, Cesareni G. *Modified phage peptide libraries as a tool to study specificity of phosphorylation and recognition of tyrosine containing peptides*. J Mol Biol. 1997 Jun 27;269(5):694-703.
 296. He LZ, Tribioli C, Rivi R, Peruzzi D, **Pelicci PG**, Soares V, Cattoretti G, Pandolfi PP. *Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice*. Proc Natl Acad Sci U S A. 1997 May 13;94(10):5302-7.
 297. Giordano V, De Falco G, Chiari R, Quinto I, **Pelicci PG**, Bartholomew L, Delmastro P, Gadina M, Scala G. *Shc mediates IL-6 signaling by interacting with gp130 and Jak2 kinase*. J Immunol. 1997 May 1;158(9):4097-103.
 298. Brown D, Kogan S, Lagasse E, Weissman I, Alcalay M, **Pelicci PG**, Atwater S, Bishop JM. *A PMLRARalpha transgene initiates murine acute promyelocytic leukemia*. Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2551-6.
 299. Rogaia D, Grignani F, Carbone R, Riganelli D, LoCoco F, Nakamura T, Croce CM, Di Fiore PP, **Pelicci PG**. *The localization of the HRX/ALL1 protein to specific nuclear subdomains is altered by fusion with its eps15 translocation partner*. Cancer Res. 1997 Mar 1;57(5):799-802.
 300. Tortora G, Damiano V, Bianco C, Baldassarre G, Bianco AR, Lanfrancone L, **Pelicci PG**, Ciardiello F. *The R1alpha subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor*. Oncogene. 1997 Feb 27;14(8):923-8.
 301. Migliaccio E, Mele S, Salcini AE, Pelicci G, Lai KM, Superti-Furga G, Pawson T, Di Fiore PP, Lanfrancone L, **Pelicci PG**. *Opposite effects of the p52shc/p46shc and p66shc splicing isoforms on the EGF receptor-MAP kinase-fos signalling pathway*. EMBO J. 1997 Feb 17;16(4):706-16.
 302. Casini T, Grignani F, **Pelicci PG**. *Genetics of APL and the molecular basis of retinoic acid treatment*. Int J Cancer. 1997 Feb 7;70(4):473-4.
 303. Grisolan JL, Wesselschmidt RL, **Pelicci PG**, Ley TJ. *Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences*. Blood. 1997 Jan 15;89(2):376-87.
 304. Iannolo G, Salcini AE, Gaidarov I, Goodman OB Jr, Baulida J, Carpenter G, **Pelicci PG**, Di Fiore PP, Keen JH. *Mapping of the molecular determinants involved in the interaction between eps15 and AP-2*. Cancer Res. 1997 Jan 15;57(2):240-5.
 305. Sacchi S, Russo D, Avvisati G, Dastoli G, Lazzarino M, **Pelicci PG**, Bonora MR, Visani G, Grassi C, Iacona I, Luzzi L, Vanzanelli P. *All-trans retinoic acid in hematological malignancies, an update*. GER (Gruppo Ematologico Retinoidi). Haematologica. 1997 Jan-Feb;82(1):106-21. Review.
-
- 1996
306. Gambacorta M, Flenghi L, Fagioli M, Pileri S, Leoncini L, Bigerna B, Pacini R, Tanci LN, Pasqualucci L, Ascani S, Mencarelli A, Liso A, **Pelicci PG**, Falini B. *Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues*. Am J Pathol. 1996 Dec;149(6):2023-35.

307. Brizzi MF, Dentelli P, Lanfranccone L, Rosso A, **Pelicci PG**, Pegoraro L. *Discrete protein interactions with the Grb2/c-Cbl complex in SCF- and TPO-mediated myeloid cell proliferation.* Oncogene. 1996 Nov 21;13(10):2067-76.
308. Raelson JV, Nervi C, Rosenauer A, Benedetti L, Monczak Y, Pearson M, **Pelicci PG**, Miller WH Jr. *The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells.* Blood. 1996 Oct 15;88(8):2826-32.
309. Effects on differentiation by the promyelocytic leukemia PML/RARalpha protein depend on the fusion of the PML protein dimerization and RARalpha DNA binding domains. Grignani F, Testa U, Rogaia D, Ferrucci PF, Samoggia P, Pinto A, Aldinucci D, Gelmetti V, Fagioli M, Alcalay M, Seeler J, Grignani F, Nicoletti I, Peschle C, **Pelicci PG**. EMBO J. 1996 Sep 16;15(18):4949-58.
310. Milia E, Di Somma MM, Baldoni F, Chiari R, Lanfranccone L, **Pelicci PG**, Telford JL, Baldari CT. *The aminoterminal phosphotyrosine binding domain of Shc associates with ZAP-70 and mediates TCR dependent gene activation.* Oncogene. 1996 Aug 15;13(4):767-75.
311. Pelicci G, Dente L, De Giuseppe A, Verducci-Galletti B, Giuli S, Mele S, Vetriani C, Giorgio M, Pandolfi PP, Cesareni G, **Pelicci PG**. *A family of Shc related proteins with conserved PTB, CH1 and SH2 regions.* Oncogene. 1996 Aug 1;13(3):633-41.
312. Brunel V, Lafage-Pochitaloff M, Alcalay M, **Pelicci PG**, Birg F. *Variant and masked translocations in acute promyelocytic leukemia.* Leuk Lymphoma. 1996 Jul;22(3-4):221-8. Review.
313. Bonfini L, Migliaccio E, Pelicci G, Lanfranccone L, **Pelicci PG**. *Not all Shc's roads lead to Ras.* Trends Biochem Sci. 1996 Jul;21(7):257-61. Review.
314. Fournier E, Rosnet O, Marchetto S, Turck CW, Rottapel R, **Pelicci PG**, Birnbaum D, Borg JP. *Interaction with the phosphotyrosine binding domain/phosphotyrosine interacting domain of SHC is required for the transforming activity of the FLT4/VEGFR3 receptor tyrosine kinase.* J Biol Chem. 1996 May 31;271(22):12956-63.
315. Morosetti R, Grignani F, Liberatore C, **Pelicci PG**, Schiller GJ, Kizaki M, Bartram CR, Miller CW, Koeffler HP. *Infrequent alterations of the RAR alpha gene in acute myelogenous leukemias, retinoic acid-resistant acute promyelocytic leukemias, myelodysplastic syndromes, and cell lines.* Blood. 1996 May 15;87(10):4399-403.
316. Flenghi L, Bigerna B, Fizzotti M, Venturi S, Pasqualucci L, Pileri S, Ye BH, Gambacorta M, Pacini R, Baroni CD, Pescarmona E, Anagnostopoulos I, Stein H, Asdrubali G, Martelli MF, **Pelicci PG**, Dalla-Favera R, Falini B. *Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein amino-terminal region.* Am J Pathol. 1996 May;148(5):1543-55.
317. Lotti LV, Lanfranccone L, Migliaccio E, Zompetta C, Pelicci G, Salcini AE, Falini B, **Pelicci PG**, Torrisi MR. *Sch proteins are localized on endoplasmic reticulum membranes and are redistributed after tyrosine kinase receptor activation.* Mol Cell Biol. 1996 May;16(5):1946-54.
318. Benedetti L, Grignani F, Scicchitano BM, Jetten AM, Diverio D, Lo Coco F, Avvisati G, Gambacorti-Passerini C, Adamo S, Levin AA, **Pelicci PG**, Nervi C. *Retinoid-induced differentiation of acute promyelocytic leukemia involves PML-RARalpha-mediated increase of type II transglutaminase.* Blood. 1996 Mar 1;87(5):1939-50.
319. Chen Y, Grall D, Salcini AE, **Pelicci PG**, Pouyssegur J, Van Obberghen-Schilling E. *Shc adaptor proteins are key transducers of mitogenic signaling mediated by the G protein-coupled thrombin receptor.* EMBO J. 1996 Mar 1;15(5):1037-44.
320. Falini B, Bigerna B, Pasqualucci L, Fizzotti M, Martelli MF, Pileri S, Pinto A, Carbone A, Venturi S, Pacini R, Cattoretti G, Pescarmona E, Lo Coco F, **Pelicci PG**, Anagnostopoulos I, Dalla-Favera R, Flenghi L. *Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease.* Blood. 1996 Jan 15;87(2):465-71.
321. Pathogenetic role of the PML1RAR alpha fusion protein in acute promyelocytic leukemia. Grignani F, **Pelicci PG**. Curr Top Microbiol Immunol. 1996;211:269-78. Review.

1995

322. Ricci A, Lanfranccone L, Chiari R, Belardo G, Pertica C, Natali PG, **Pelicci PG**, Segatto O. *Analysis of protein-protein interactions involved in the activation of the Shc/Grb-2 pathway by the ErbB-2 kinase.* Oncogene. 1995 Oct 19;11(8):1519-29.
323. Lo Coco F, Diverio D, Avvisati G, Mandelli F, Biondi A, **Pelicci PG**. *On the differentiative mode of action of All-trans retinoic acid in acute promyelocytic leukemia.* Blood. 1995 Oct 15;86(8):3264-5.

324. Wong WT, Schumacher C, Salcini AE, Romano A, Castagnino P, **Pelicci PG**, Di Fiore PP. *A protein-binding domain, EH, identified in the receptor tyrosine kinase substrate Eps15 and conserved in evolution.* Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9530-4.
325. Pelicci G, Lanfrancone L, Salcini AE, Romano A, Mele S, Grazia Borrello M, Segatto O, Di Fiore PP, **Pelicci PG**. *Constitutive phosphorylation of Shc proteins in human tumors.* Oncogene. 1995 Sep 7;11(5):899-907.
326. Lavau C, Marchio A, Fagioli M, Jansen J, Falini B, Lebon P, Grosveld F, Pandolfi PP, **Pelicci PG**, Dejean A. *The acute promyelocytic leukaemia-associated PML gene is induced by interferon.* Oncogene. 1995 Sep 7;11(5):871-6.
327. Rogaia D, Grignani F, Grignani F, Nicoletti I, **Pelicci PG**. *The acute promyelocytic leukemia-specific PML/RAR alpha fusion protein reduces the frequency of commitment to apoptosis upon growth factor deprivation of GM-CSF-dependent myeloid cells.* Leukemia. 1995 Sep;9(9):1467-72.
328. Avantiaggiato V, Pandolfi PP, Ruthardt M, Hawe N, Acampora D, **Pelicci PG**, Simeone A. *Developmental analysis of murine Promyelocyte Leukemia Zinc Finger (PLZF) gene expression: implications for the neuromeric model of the forebrain organization.* J Neurosci. 1995 Jul;15(7 Pt 1):4927-42.
329. Matoskova B, Wong WT, Salcini AE, **Pelicci PG**, Di Fiore PP. *Constitutive phosphorylation of eps8 in tumor cell lines: relevance to malignant transformation.* Mol Cell Biol. 1995 Jul;15(7):3805-12.
330. Fizzotti M, Cimino G, Pisegna S, Alimena G, Quartarone C, Mandelli F, **Pelicci PG**, Lo Coco F. *Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features.* Blood. 1995 May 15;85(10):2685-90.
331. Pelicci G, Giordano S, Zhen Z, Salcini AE, Lanfrancone L, Bardelli A, Panayotou G, Waterfield MD, Ponzetto C, **Pelicci PG**, et al. *The mitogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein.* Oncogene. 1995 Apr 20;10(8):1631-8.
332. Baldari CT, Pelicci G, Di Somma MM, Milia E, Giuli S, **Pelicci PG**, Telford JL. *Inhibition of CD4/p56lck signaling by a dominant negative mutant of the Shc adaptor protein.* Oncogene. 1995 Mar 16;10(6):1141-7.
333. Lanfrancone L, Pelicci G, Brizzi MF, Aronica MG, Casciari C, Giuli S, Pegoraro L, Pawson T, **Pelicci PG**, Arouica MG. *Overexpression of Shc proteins potentiates the proliferative response to the granulocyte-macrophage colony-stimulating factor and recruitment of Grb2/SoS and Grb2/p140 complexes to the beta receptor subunit.* Oncogene. 1995 Mar 2;10(5):907-17.
334. *Acute promyelocytic leukemia cases with nonreciprocal PML/RARa or RARa/PML fusion genes.* Lafage-Pochitaloff M, Alcalay M, Brunel V, Longo L, Sainty D, Simonetti J, Birg F, **Pelicci PG**. Blood. 1995 Mar 1;85(5):1169-74.
335. Grignani F, Testa U, Fagioli M, Barberi T, Masciulli R, Mariani G, Peschle C, **Pelicci PG**. *Promyelocytic leukemia-specific PML-retinoic acid alpha receptor fusion protein interferes with erythroid differentiation of human erythroleukemia K562 cells.* Cancer Res. 1995 Jan 15;55(2):440-3.

1994

336. Salcini AE, McGlade J, Pelicci G, Nicoletti I, Pawson T, **Pelicci PG**. *Formation of Shc-Grb2 complexes is necessary to induce neoplastic transformation by overexpression of Shc proteins.* Oncogene. 1994 Oct;9(10):2827-36.
337. Testa U, Grignani F, Barberi T, Fagioli M, Masciulli R, Ferrucci PF, Seripa D, Camagna A, Alcalay M, **Pelicci PG**, et al. *PML/RAR alpha+ U937 mutant and NB4 cell lines: retinoic acid restores the monocytic differentiation response to vitamin D3.* Cancer Res. 1994 Aug 15;54(16):4508-15.
338. Trecca D, Longo L, Biondi A, Cro L, Calori R, Grignani F, Maiolo AT, **Pelicci PG**, Neri A. *Analysis of p53 gene mutations in acute myeloid leukemia.* Am J Hematol. 1994 Aug;46(4):304-9.
339. Vainikka S, Joukov V, Wennström S, Bergman M, **Pelicci PG**, Alitalo K. *Signal transduction by fibroblast growth factor receptor-4 (FGFR-4). Comparison with FGFR-1.* J Biol Chem. 1994 Jul 15;269(28):18320-6.
340. Giorgetti S, **Pelicci PG**, Pelicci G, Van Obberghen E. *Involvement of Src-homology/collagen (SHC) proteins in signaling through the insulin receptor and the insulin-like-growth-factor-I-receptor.* Eur J Biochem. 1994 Jul 1;223(1):195-202.
341. Diverio D, Pandolfi PP, Rossi V, Biondi A, **Pelicci PG**, Lo Coco F. *Monitoring of treatment outcome in acute promyelocytic leukemia by RT-PCR.* Leukemia. 1994 Jul;8(7):1105-7. Review.
342. Borrello MG, Pelicci G, Arighi E, De Filippis L, Greco A, Bongarzone I, Rizzetti M, **Pelicci PG**, Pierotti MA. *The oncogenic versions of the Ret and Trk tyrosine kinases bind Shc and Grb2 adaptor proteins.* Oncogene. 1994 Jun;9(6):1661-8.
343. Fagioli M, Grignani F, Ferrucci PF, Alcalay M, Mencarelli A, Nicoletti I, Grignani F, **Pelicci PG**. *Effect of the acute promyelocytic leukemia PML/RAR alpha protein on differentiation and survival of myeloid precursors.* Leukemia. 1994 Apr;8 Suppl 1:S7-11.

344. Lo Coco F, D'Adamo F, Diverio D, **Pelicci PG**, Saglio G. *Polyclonal hemopoiesis in leukemia patients following molecularly documented remission.* Leukemia. 1994 Apr;8 Suppl 1:S137-9.
345. *Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.* Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, **Pelicci PG**, Arlinghaus R, Pawson T. EMBO J. 1994 Feb 15;13(4):764-73.
346. Lanfrancone L, Pelicci G, **Pelicci PG**. *Cancer genetics.* Curr Opin Genet Dev. 1994 Feb;4(1):109-19. Review.
347. Lo Coco F, **Pelicci PG**, Biondi A. *Clinical relevance of the PML/RAR- α gene rearrangement in acute promyelocytic leukaemia.* Leuk Lymphoma. 1994 Feb;12(5-6):327-32. Review.
348. Dilworth SM, Brewster CE, Jones MD, Lanfrancone L, Pelicci G, **Pelicci PG**. *Transformation by polyoma virus middle T-antigen involves the binding and tyrosine phosphorylation of Shc.* Nature. 1994 Jan 6;367(6458):87-90.
349. Grignani F, Fagioli M, Alcalay M, Longo L, Pandolfi PP, Donti E, Biondi A, Lo Coco F, Grignani F, **Pelicci PG**. *Acute promyelocytic leukemia: from genetics to treatment.* Blood. 1994 Jan 1;83(1):10-25. Review.
350. Diverio D, Pandolfi PP, Rossi V, Biondi A, **Pelicci PG**, Lo Coco F. *Monitoring of treatment outcome in acute promyelocytic leukemia by RT-PCR.* Leukemia. 1994;8 Suppl 2:S63-5.

1993

351. Delia D, Aiello A, Lombardi L, **Pelicci PG**, Grignani F, Grignani F, Formelli F, Menard S, Costa A, Veronesi U, et al. *N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid.* Cancer Res. 1993 Dec 15;53(24):6036-41.
352. Longo L, Trecca D, Biondi A, Lo Coco F, Grignani F, Maiolo AT, **Pelicci PG**, Neri A. *Frequency of RAS and p53 mutations in acute promyelocytic leukemias.* Leuk Lymphoma. 1993 Nov;11(5-6):405-10.
353. Dermime S, Grignani F, Clerici M, Nervi C, Sozzi G, Talamo GP, Marchesi E, Formelli F, Parmiani G, **Pelicci PG**, Gambacorti-Passerini C. *Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the pml/RAR alpha protein.* Blood. 1993 Sep 1;82(5):1573-7.
354. Segatto O, Pelicci G, Giuli S, Digiesi G, Di Fiore PP, McGlade J, Pawson T, **Pelicci PG**. *Shc products are substrates of erbB-2 kinase.* Oncogene. 1993 Aug;8(8):2105-12.
355. Lo Coco F, **Pelicci PG**, D'Adamo F, Diverio D, Alimena G, Montefusco E, Arcese W, Avvisati G, De Felice L, Meloni G, et al. *Polyclonal hematopoietic reconstitution in leukemia patients at remission after suppression of specific gene rearrangements.* Blood. 1993 Jul 15;82(2):606-12.
356. Grignani F, Fagioli M, Ferrucci PF, Alcalay M, **Pelicci PG**. *The molecular genetics of acute promyelocytic leukemia.* Blood Rev. 1993 Jun;7(2):87-93. Review.
357. Davis S, Crino L, Tonato M, Darwish S, **Pelicci PG**, Grignani F. *A prospective analysis of chemotherapy following surgical resection of clinical stage I-II small-cell lung cancer.* Am J Clin Oncol. 1993 Apr;16(2):93-5.
358. Huebner K, Druck T, LaForgia S, Lasota J, Croce CM, Lanfrancone L, Donti E, Pengue G, La Mantia G, **Pelicci PG**, et al. *Chromosomal localization of four human zinc finger cDNAs.* Hum Genet. 1993 Apr;91(3):217-22.
359. Gambacorti-Passerini C, Grignani F, Arienti F, Pandolfi PP, **Pelicci PG**, Parmiani G. *Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells.* Blood. 1993 Mar 1;81(5):1369-75.
360. Biondi A, Rambaldi A, Pandolfi PP, Alcalay M, Longo L, Rossi V, Giudici G, Lo Coco F, **Pelicci PG**. *Molecular genetics of the t(15;17) translocation in acute promyelocytic leukemia.* Recent Results Cancer Res. 1993;131:345-59. Review.

1992

361. Rozakis-Adcock M, McGlade J, Mbamalu G, Pelicci G, Daly R, Li W, Batzer A, Thomas S, Brugge J, **Pelicci PG**, Schlessinger J, Pawson T, et al. *Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases.* Nature. 1992 Dec 17;360(6405):689-92.
362. Lanfrancone L, Boraschi D, Ghiara P, Falini B, Grignani F, Peri G, Mantovani A, **Pelicci PG**. *Human peritoneal mesothelial cells produce many cytokines (granulocyte colony-stimulating factor [CSF], granulocyte-monocyte-CSF, macrophage-CSF, interleukin-1 [IL-1], and IL-6) and are activated and stimulated to grow by IL-1.* Blood. 1992 Dec 1;80(11):2835-42.
363. McGlade J, Cheng A, Pelicci G, **Pelicci PG**, Pawson T. *Shc proteins are phosphorylated and regulated by the v-Src and v-Fps protein-tyrosine kinases.* Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):8869-73.

364. Pelicci G, Lanfranccone L, Grignani F, McGlade J, Cavallo F, Forni G, Nicoletti I, Grignani F, Pawson T, **Pelicci PG**. *A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction.* Cell. 1992 Jul 10;70(1):93-104.
365. Nervi C, Poindexter EC, Grignani F, Pandolfi PP, Lo Coco F, Avvisati G, **Pelicci PG**, Jetten AM. *Characterization of the PML-RAR alpha chimeric product of the acute promyelocytic leukemia-specific t(15;17) translocation.* Cancer Res. 1992 Jul 1;52(13):3687-92.
366. Fagioli M, Alcalay M, Pandolfi PP, Venturini L, Mencarelli A, Simeone A, Acampora D, Grignani F, **Pelicci PG**. *Alternative splicing of PML transcripts predicts coexpression of several carboxy-terminally different protein isoforms.* Oncogene. 1992 Jun;7(6):1083-91.
367. *Expression pattern of the RAR alpha-PML fusion gene in acute promyelocytic leukemia.* Alcalay M, Zangrilli D, Fagioli M, Pandolfi PP, Mencarelli A, Lo Coco F, Biondi A, Grignani F, **Pelicci PG**. Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):4840-4.
368. Lanfranccone L, Pengue G, Pandolfi PP, Salcini AE, Giacomucci A, Longo L, Donti E, De Luca P, La Mantia G, **Pelicci PG**, et al. *Structural and functional organization of the HF.10 human zinc finger gene (ZNF35) located on chromosome 3p21-p22.* Genomics. 1992 Apr;12(4):720-8.
369. Lo Coco F, Diverio D, D'Adamo F, Avvisati G, Alimena G, Nanni M, Alcalay M, Pandolfi PP, **Pelicci PG**. *PML/RAR-alpha rearrangement in acute promyelocytic leukaemias apparently lacking the t(15;17) translocation.* Eur J Haematol. 1992 Mar;48(3):173-6.

1991

370. Donti E, Lanfranccone L, **Pelicci PG**, Birnie GD, Dalla-Favera R. *Loss of amplification and appearance of a novel translocation site of the c-myc oncogene in HL-60 leukemia cells.* Cancer Genet Cytogenet. 1991 Oct 1;56(1):57-64.
371. Donti E, Longo L, **Pelicci PG**. *Chromosomal localization of the APL t(15;17) breakpoints by molecular cytogenetic analysis.* Cancer Genet Cytogenet. 1991 Jul 15;54(2):265-6.
372. Pandolfi PP, Grignani F, Alcalay M, Mencarelli A, Biondi A, LoCoco F, Grignani F, **Pelicci PG**. *Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties.* Oncogene. 1991 Jul;6(7):1285-92.
373. **Pelicci PG**, Grignani F. *Molecular biology in onco-hematology.* Haematologica. 1991 Jun;76 Suppl 3:11-8. Review.
374. Falini B, Flenghi L, Fagioli M, **Pelicci PG**, Stein H, Bigerna B, Pileri S, Martelli MF. *Expression of the intestinal T-lymphocyte associated molecule HML-1: analysis of 75 non-Hodgkin's lymphomas and description of the first HML-1 positive T-lymphoblastic tumour.* Histopathology. 1991 May;18(5):421-6.
375. Moretta L, Ciccone E, Ferrini S, **Pelicci PG**, Mingari MC, Zeromski J, Bottino C, Grossi C, Moretta A. *Molecular and cellular analysis of human T lymphocytes expressing gamma delta T-cell receptor.* Immunol Rev. 1991 Apr;120:117-35. Review.
376. Aversa F, **Pelicci PG**, Terenzi A, Carotti A, Felicini R, Mencarelli A, Donti E, Latini P, Aristei C, Martelli MF. *Results of T-depleted BMT in chronic myelogenous leukaemia after a conditioning regimen that included thiotepea.* Bone Marrow Transplant. 1991;7 Suppl 2:24.

1990

377. Longo L, Donti E, Mencarelli A, Avanzi G, Pegoraro L, Alimena G, Tabilio A, Venti G, Grignani F, **Pelicci PG**. *Mapping of chromosome 17 breakpoints in acute myeloid leukemias.* Oncogene. 1990 Oct;5(10):1557-63.
378. Pelicci G, Pagliacci MC, Lanfranccone L, **Pelicci PG**, Grignani F, Nicoletti I. *Inhibitory effect of the somatostatin analog octreotide on rat pituitary tumor cell (GH3) proliferation in vitro.* J Endocrinol Invest. 1990 Sep;13(8):657-62.
379. Moretta A, Bottino C, Pende D, Tripodi G, Orengo AM, Millo R, **Pelicci PG**, Ciccone E, Moretta L. *Human T lymphocytes expressing TCR gamma/delta* Res Immunol. 1990 Sep;141(7):630-5.
380. Fagioli M, Ciccone E, Bottino C, Falini B, Grignani F, Moretta A, Moretta L, **Pelicci PG**. *The C gamma 1-encoded disulphide-linked and the C gamma 2-encoded nondisulphide-linked forms of the gamma/delta heterodimer use different gamma and delta variable regions.* Blood. 1990 Jul 15;76(2):279-84.
381. Carè A, **Pelicci PG**, Meccia E, Fagioli M, Testa U, Ciccone E, Moretta A, Moretta L, Peschle C. *Natural killer cells carry the germ-line configuration of the T cell receptor delta chain gene and heterogeneously express six distinct delta transcripts.* Eur J Immunol. 1990 Apr;20(4):939-42.
382. Donti E, Lanfranccone L, Huebner K, Pascucci A, Venti G, Pengue G, Grignani F, Croce CM, Lania L, **Pelicci PG**. *Localization of the human HF.10 finger gene on a chromosome region (3p21-22) frequently deleted in human cancers.* Hum Genet. 1990 Apr;84(5):391-5.

383. Alcalay M, Antolini F, Van de Ven WJ, Lanfranccone L, Grignani F, **Pelicci PG**. *Characterization of human and mouse c-fes cDNA clones and identification of the 5' end of the gene*. Oncogene. 1990 Mar;5(3):267-75.
384. Lania L, Donti E, Pannuti A, Pascucci A, Pengue G, Feliciello I, La Mantia G, Lanfranccone L, **Pelicci PG**. *cDNA isolation, expression analysis, and chromosomal localization of two human zinc finger genes*. Genomics. 1990 Feb;6(2):333-40.
385. Fagioli M, Carè A, Ciccone E, Moretta L, Moretta A, Testa U, Falini B, Grignani F, Peschle C, **Pelicci PG**. *Molecular studies on LAK cells*. Ann Ist Super Sanita. 1990;26(3-4):357-68.

1989

386. Falini B, Flenghi L, Fagioli M, Martelli MF, Pileri S, Grignani F, Beltrami A, Novero D, **Pelicci PG**. *T-lymphoblastic lymphomas expressing the non-disulfide-linked form of the T-cell receptor gamma/delta: characterization with monoclonal antibodies and genotypic analysis*. Blood. 1989 Nov 15;74(7):2501-7.
387. Falini B, Flenghi L, Fagioli M, Stein H, Schwarting R, Riccardi C, Manocchio I, Pileri S, **Pelicci PG**, Lanfranccone L. *Evolutionary conservation in various mammalian species of the human proliferation-associated epitope recognized by the Ki-67 monoclonal antibody*. J Histochem Cytochem. 1989 Oct;37(10):1471-8.
388. Donti E, Montanucci M, Longo L, Mencarelli A, Pandolfi P, Tabilio A, Nanni M, Alimena G, Avanzi G, Pegoraro L, Grignani F, **Pelicci PG**. *The myeloperoxidase gene in acute promyelocytic leukemia*. Science. 1989 May 19;244(4906):824-5.
389. Lanfranccone L, Mannoni P, Pebusque MJ, Carè A, Peschle C, Grignani F, **Pelicci PG**. *Expression pattern of c-fes oncogene mRNA in human myeloid cells*. Int J Cancer Suppl. 1989;4:35-8.

1988

390. Pannuti A, Lanfranccone L, Pascucci A, **Pelicci PG**, La Mantia G, Lania L. *Isolation of cDNAs encoding finger proteins and measurement of the corresponding mRNA levels during myeloid terminal differentiation*. Nucleic Acids Res. 1988 May 25;16(10):4227-37.
391. Knowles DM, Chamulak G, Subar M, **Pelicci PG**, Dugan M, Burke JS, Raphael B, Dalla-Favera R. *Clinicopathologic, immunophenotypic, and molecular genetic analysis of AIDS-associated lymphoid neoplasia. Clinical and biologic implications*. Pathol Annu. 1988;23 Pt 2:33-67. Review.

1987

392. Neri A, Jakobiec FA, **Pelicci PG**, Dalla-Favera R, Knowles DM 2nd. *Immunoglobulin and T cell receptor beta chain gene rearrangement analysis of ocular adnexal lymphoid neoplasms: clinical and biologic implications*. Blood. 1987 Nov;70(5):1519-29.
393. **Pelicci PG**, Allavena P, Subar M, Rambaldi A, Pirelli A, Di Bello M, Barbui T, Knowles DM 2nd, Dalla-Favera R, Mantovani A. *T cell receptor (alpha, beta, gamma) gene rearrangements and expression in normal and leukemic large granular lymphocytes/natural killer cells*. Blood. 1987 Nov;70(5):1500-8.
394. **Pelicci PG**, Subar M, Weiss A, Dalla-Favera R, Littman DR. *Molecular diversity of the human T-gamma constant region genes*. Science. 1987 Aug 28;237(4818):1051-5.
395. Seremetis SV, **Pelicci PG**, Tabilio A, Ubriaco A, Grignani F, Cuttner J, Winchester RJ, Knowles DM 2nd, Dalla-Favera R. *High frequency of clonal immunoglobulin or T cell receptor gene rearrangements in acute myelogenous leukemia expressing terminal deoxyribonucleotidyltransferase*. J Exp Med. 1987 Jun 1;165(6):1703-12.
396. Knowles DM 2nd, **Pelicci PG**, Dalla-Favera R. *Immunoglobulin and T cell receptor beta chain gene DNA probes in the diagnosis and classification of human lymphoid neoplasia*. Mol Cell Probes. 1987 Mar;1(1):15-31. Review.
397. Barletta C, **Pelicci PG**, Kenyon LC, Smith SD, Dalla-Favera R. *Relationship between the c-myc locus and the 6q-chromosomal aberration in leukemias and lymphomas*. Science. 1987 Feb 27;235(4792):1064-7.
398. **Pelicci PG**, Neri A, Knowles DM 2nd, Littman DR, Dalla-Favera R, Subar M. *Arrangements and rearrangements of the human T-cell receptor gamma gene*. Ann N Y Acad Sci. 1987;511:232-45.
399. Dalla-Favera R, Lombardi L, **Pelicci PG**, Lanfranccone L, Cesarman E, Neri A. *Mechanism of activation and biological role of the c-myc oncogene in B-cell lymphomagenesis*. Ann N Y Acad Sci. 1987;511:207-18. Review.
400. Bonetti F, Chilosi M, Menestrina F, Scarpa A, **Pelicci PG**, Amorosi E, Fiore-Donati L, Knowles DM 2nd. *Immunohistological analysis of Rosai-Dorfman histiocytosis. A disease of S-100 + CD1-histiocytes*. Virchows Arch A Pathol Anat Histopathol. 1987;411(2):129-35.

1986

401. **Pelicci PG**, Knowles DM 2nd, Arlin ZA, Wieczorek R, Luciw P, Dina D, Basilico C, Dalla-Favera R. *Multiple monoclonal B cell expansions and c-myc oncogene rearrangements in acquired immune deficiency syndrome-related lymphoproliferative disorders. Implications for lymphomagenesis.* J Exp Med. 1986 Dec 1;164(6):2049-60.
402. Knowles DM 2nd, Neri A, **Pelicci PG**, Burke JS, Wu A, Winberg CD, Sheibani K, Dalla-Favera R. *Immunoglobulin and T-cell receptor beta-chain gene rearrangement analysis of Hodgkin's disease: implications for lineage determination and differential diagnosis.* Proc Natl Acad Sci U S A. 1986 Oct;83(20):7942-6.
403. Pantazis P, Lanfranccone L, **Pelicci PG**, Dalla-Favera R, Antoniades HN. *Human leukemia cells synthesize and secrete proteins related to platelet-derived growth factor.* Proc Natl Acad Sci U S A. 1986 Aug;83(15):5526-30.
404. Knowles DM 2nd, **Pelicci PG**, Dalla-Favera R. *T-cell receptor beta chain gene rearrangements: genetic markers of T-cell lineage and clonality.* Hum Pathol. 1986 Jun;17(6):546-51.
405. **Pelicci PG**, Knowles DM 2nd, Magrath I, Dalla-Favera R. *Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma.* Proc Natl Acad Sci U S A. 1986 May;83(9):2984-8.
406. Falini B, Tabilio A, **Pelicci PG**, Dalla Favera R, Donti E, Rambotti P, Grignani F, Martelli MF. *T-cell receptor beta-chain gene rearrangement in a case of Ph1-positive chronic myeloid leukemia blast crisis.* Br J Haematol. 1986 Apr;62(4):776-9.
407. Foa R, **Pelicci PG**, Migone N, Lauria F, Pizzolo G, Flug F, Knowles DM 2nd, Dalla-Favera R. *Analysis of T-cell receptor beta chain (T beta) gene rearrangements demonstrates the monoclonal nature of T-cell chronic lymphoproliferative disorders.* Blood. 1986 Jan;67(1):247-50.
408. Lanfranccone L, **Pelicci PG**, Dalla-Favera R. *Structure and expression of translocated c-myc oncogenes: specific differences in endemic, sporadic and AIDS-associated forms of Burkitt lymphomas.* Curr Top Microbiol Immunol. 1986;132:257-65.
409. Rambaldi A, Allavena P, Pirelli A, Di Bello M, Rossini S, Bassan R, Barbui T, **Pelicci PG**, Dalla Favera R, Mantovani A. *Immunological and genotypic analysis of human T gamma-lymphoproliferative disorders.* Ric Clin Lab. 1986 Jan-Mar;16(1):29-35.

1985

410. Rambaldi A, **Pelicci PG**, Allavena P, Knowles DM 2nd, Rossini S, Bassan R, Barbui T, Dalla-Favera R, Mantovani A. *T cell receptor beta chain gene rearrangements in lymphoproliferative disorders of large granular lymphocytes/natural killer cells.* J Exp Med. 1985 Dec 1;162(6):2156-62.
411. Knowles DM 2nd, Dodson L, Burke JS, Wang JM, Bonetti F, **Pelicci PG**, Flug F, Dalla-Favera R, Wang CY. *Slg-E- ("null-cell") non-Hodgkin's lymphomas. Multiparametric determination of their B- or T-cell lineage.* Am J Pathol. 1985 Sep;120(3):356-70.
412. **Pelicci PG**, Knowles DM 2nd, Dalla Favera R. *Lymphoid tumors displaying rearrangements of both immunoglobulin and T cell receptor genes.* J Exp Med. 1985 Sep 1;162(3):1015-24.
413. Knowles DM, Dalla-Favera R, **Pelicci PG**. *T-cell-receptor beta-chain gene rearrangements.* Lancet. 1985 Jul 20;2(8447):159-60.
414. Flug F, **Pelicci PG**, Bonetti F, Knowles DM 2nd, Dalla-Favera R. *T-cell receptor gene rearrangements as markers of lineage and clonality in T-cell neoplasms.* Proc Natl Acad Sci U S A. 1985 May;82(10):3460-4.
415. Pantazis P, **Pelicci PG**, Dalla-Favera R, Antoniades HN. *Synthesis and secretion of proteins resembling platelet-derived growth factor by human glioblastoma and fibrosarcoma cells in culture.* Proc Natl Acad Sci U S A. 1985 Apr;82(8):2404-8.

1984

416. **Pelicci PG**, Lanfranccone L, Brathwaite MD, Wolman SR, Dalla-Favera R. *Amplification of the c-myc oncogene in a case of human acute myelogenous leukemia.* Science. 1984 Jun 8;224(4653):1117-21.
417. Louache F, Villeval JL, **Pelicci PG**, Rouis M, Titeux M, Henri A, Rochant H, Thomopoulos P, Testa U. *Characterization of phorbol esters binding to K 562 cells.* Anticancer Res. 1984 Jan-Apr;4(1-2):33-9.
418. **Pelicci PG**, Testa U, Thomopoulos P, Tabilio A, Vainchenker W, Titeux M, Gourdin MF, Rochant H. *Inhibition of transferrin binding and iron uptake of hematopoietic cell lines by phorbol esters.* Leuk Res. 1984;8(4):597-609.

1983

419. Tabilio A, **Pelicci PG**, Vinci G, Mannoni P, Civin CI, Vainchenker W, Testa U, Lipinski M, Rochant H, Breton-Gorius J. *Myeloid and megakaryocytic properties of K-562 cell lines*. Cancer Res. 1983 Oct;43(10):4569-74.
420. Testa U, **Pelicci PG**, Thomopoulos P, Titeux M, Rochant H. *The number of the Trf receptors on human hematopoietic cell lines is influenced by membrane phospholipids*. Biochem Int. 1983 Aug;7(2):169-78.
421. Villeval JL, **Pelicci PG**, Tabilio A, Titeux M, Henri A, Houesche F, Thomopoulos P, Vainchenker W, Garbaz M, Rochant H, Breton-Gorius J, Edwards PA, Testa U. *Erythroid properties of K562 cells. Effect of hemin, butyrate and TPA induction*. Exp Cell Res. 1983 Jul;146(2):428-35.
422. **Pelicci PG**, Tabilio A, Vainchenker W, Testa U. *The role of phorbol esters in the control of the proliferation and differentiation of hematopoietic cells*. Haematologica. 1983 May-Jun;68(3):411-26. Review.

1982

423. **Pelicci PG**, Tabilio A, Thomopoulos P, Titeux M, Vainchenker W, Rochant H, Testa U. *Hemin regulates the expression of transferrin receptors in human hematopoietic cell lines*. FEBS Lett. 1982 Aug 23;145(2):350-4.

Book Chapters

1. **Pelicci PG**, Thomopoulos P, Tabilio A, Vainchenker W, Titeux M, Gourdin MF, Rochant H, Rambotti P, Martelli MF, Grignani F, Testa U: Phorbol esters inhibit transferrin binding to human hematopoietic cell lines. Frontiers in Experimental Hematology. Ed. by Torelli U, Bagnara GP, Brunelli MA, Castaldini C, Di Prisco AV. Sero Sypmposia, Roma, Vol 4:85-7, 1983.
2. Tabilio A, **Pelicci PG**, Mannoni P, Vainchenker W, Testa U, Rochant H, Breton-Gorius J, Falini B, Martelli MF, Grignani F: Modulation of granulocytic and megakaryocytic differentiation markers by different inducers in the K562 cell line. Frontiers in Experimental Hematology. Ed. by Torelli U, Bagnara GP, Brunelli MA, Castaldini C, Di Prisco AV. Sero Sypmposia, Roma, Vol 4:169-72, 1983.
3. Lanfranccone L, **Pelicci PG**, Cesarman E, Dalla Favera R: Mechanism of oncogene activation in human hematopoietic tumors. In: New trends in experimental Hematology: Oncogenes - stem cells - Bone Marrow Transplantation. Ed. by Peschle C and Rizzoli C. Ames Sero Publ., Num. 7:196-203, 1984.
4. **Pelicci PG**, Flug F, Bonetti F, Knowles DM, Dalla Favera R: Immuglobulin and T-cell receptor gene rearrangement in B and T-cell neoplasm. In: New trends in Experimental Hematology. Oncogenes - stem cells - Bone Marrow Transplantation. Ed. by Peschle C and Rizzoli C. Ames Sero Publ., Num. 7:79-86, 1984.
5. **Pelicci PG**, Lanfranccone L, Brathwaite MD, Wolman SR, Tabilio A, Dalla Favera R: Oncogene (c-myc, c-myb) amplification in acute Myelogenous leukaemia. In: Monoclonal Antibodies in Haemopathology. Ed. by Grignani F, Martelli MF, Mason DY. Raven Press, New York, 26:79-86, 1985.
6. **Pelicci PG**, Subar M, Littman DR, Dalla Favera R: Molecular diversity of the human T gamma gene. Genotypic, Phenotypic and Functional Aspects of Hemopoiesis. Grignani F, Martelli MF, Mason D (Eds). Raven Press, New York, Vol 41:167, 1987.
7. Tabilio A, Lanfranccone L, Stefani S, **Pelicci PG**, Falzetti F, Carotti A, Grignani F, Martelli MF: Evidence favouring myeloid origin in acute undifferentiated leukemias: Absence of immunoglobulin and B-T cell receptor gene rearrangements in CD33 and/or CD13 positive acute leukemias. Genotypic, Phenotypic and Functional Aspects of hemopoiesis. Grignani F, Martelli MF, Mason D (Eds). Raven Press, New York, Vol 41:59, 1987.
8. Alcalay M, Lanfranccone L, Montanucci M, Talamo G, Grignani F, **Pelicci PG**: Structure and function of the c-fes oncogene. Oncogenes and Growth Factors in Onco-hematology. Ed. by Aglietta M, Saglio G, Gavosto F, pp 97-100, 1988.
9. Lanfranccone L, Poesz B, Tabilio A, Falcinelli F, Donti E, Grignani F, **Pelicci PG**: Normal human macrophages: a novel system to study the role of oncogenes in cell proliferation and differentiation. In: Oncogenes and Growth Factors in Onco-hematology. Ed. by Aglietta M, Saglio G, Gavosto F, pp 88-91, 1988.
10. Lania L, Pascucci A, Pannuti A, Pengue G, Feliciello I, Lanfranccone L, **Pelicci PG**, La Mantia G: Expression of human finger genes during myeloid differentiation. In: Oncogenes and Growth Factors in Onco-hematology. First National Symposium. Ed. by Aglietta M, Saglio G, Gavosto F, p. 76, 1988.

11. Testa U, Carè A, Montesoro E, Fossati C, Giannella G, Masciulli R, Fagioli M, Bulgarini D, Habetswallner D, Isacchi G, **Pelicci PG**, Peschle C: IL-2 dependent long term cultures of human LAK cells. Cytokines in hemopoiesis, oncology and AIDS, 1989.
12. Fagioli M, Carè A, Ciccone E, Moretta L, Moretta A, Meccia E, Testa U, Grignani F, Peschle C, **Pelicci PG**: Clonaggio del trascritto di 1.0 Kb da linfociti NK e g/d. Serono Symposia Reviews, 1991.
13. **Pelicci PG**, Grignani F: Acute Promyelocytic Leukemia: rearrangements of the RARa and myl genes. In: Progress and perspectives in chemoprevention. Ed. De Paolo G, Sporn M, Veronesi U. Raven Press 79:233-42, 1992.
14. Grignani F, Fagioli M, Alcalay M, Ferrucci PF, Tomassoni L, Rogaia D, Grignani F, **Pelicci PG**: The molecular genetics of acute promyelocytic leukemia. Molecular Bases of Human Diseases. Ed. by Polli EE, 1993.
15. Grignani F, Fagioli M, Alcalay M, Tomassoni L, Rogaia D, Grignani F, **Pelicci PG**: Molecular Pathogenesis of Acute Promyelocytic Leukaemia. Hematopoietic growth factors: Oncogenes and cytokines in clinical hematology. Karger, Basel, Vol. 106:148-59, 1993.
16. Alcalay M, Fagioli M, Grignani F, Ferrucci PF, Tomassoni L, Rogaia D, Liberatore C, Ruthardt M, Mencarelli A, Grignani F, **Pelicci PG**: Molecular genetics of the acute promyelocytic leukemia. Serono Symposia, Vol. 2, 1993.
17. Grignani F, Fagioli M, Alcalay M, Ferrucci PF, Tomassoni L, Rogaia D, Liberatore C, Ruthardt M, Mencarelli A, Grignani F, **Pelicci PG**: Pathogenetic relevance of the acute promyelocytic leukemia-specific PML/RARa fusion proteins. Serono Symposia, Vol. 2, 1993.
18. Grignani F, Grignani Fr, Rogaia D, Tomassoni L, Ruthardt M, Liberatore C, Ferrucci PF, **Pelicci PG**: La patogenesi molecolare della leucemia acuta promielocitica e le sue implicazioni per la diagnosi e la terapia. Haematologica, Vol.78, Supplement to No.6, December 1993.
19. Alcalay M, Grignani Fr, Ferrucci PF, Fagioli M, Mencarelli A, Grignani F, **Pelicci PG**: The acute promyelocytic leukemia PML/RARa protein affects differentiation and survival of myeloid precursor cells. Retinoids: From Basic Science to Clinical Applications, Livrea and Vidali Eds. Birkhauser Verlag Basel/ Switzerland, pp 357-66, 1994.
20. Biondi A, Rambaldi A, Rossi V, Luciano A, Cavana M, Lo Coco F, Diverio D, Pandolfi PP, Alcalay M, Bartram CR, **Pelicci PG**: PCR approach for the evaluation of minimal residual disease in acute leukemia. Molecular Diagnosis and Monitoring of Leukemia and Lymphoma, Borden, Goldman, Grignani Eds, pp 211-19, 1994.
21. Diverio D, Pandolfi PP, Biondi A, Rossi V, Rambaldi A, **Pelicci PG**, Lo Coco F: Molecular monitoring of the Acute Promyelocytic Leukemia clone following different treatment modalities. Molecular Diagnosis and Monitoring of Leukemia and Lymphoma, Borden, Goldman, Grignani Eds, pp 87-92, 1994.
22. Fagioli M, **Pelicci PG**: Structure and expression pattern of the PML gene. Normal and Malignant Hematopoiesis, Ed. Mihich and Metcalf, Plenum Press, 13:157-71, 1995.
23. Grignani F, Aversa F, Donti E, Grignani Fr, Nicoletti I, **Pelicci PG**: Leucemie acute non linfoidi. Patogenesi molecolare e terapia. Il Policlinico, Sez. Pratica, Ed. Pozzi, 102(7/8):377-89, 1995.
24. Grignani F, **Pelicci PG**: Molecular biology of acute promyelocytic leukemia. Hormons and Cancer, Ed. By Vedeckis W, Birkhauser, Boston, pp 577-605, 1996.
25. **Pelicci PG**: Tumori: marcatori genetici. Enciclopedia Medica Italiana, pp 6016-23, 2000.
26. Giorgio M, **Pelicci PG**: Mouse Models and Longevity. Oxidative Stress and Aging: diagnostic, intervention and longevity, World Scientific Publishing Co.Pte.Ltd., pp 1262-75, 2002.
27. Kajstura J, LeCapitaine N, Loredi M, Giorgio M, Mitchell TS, Valentini S, Rotatori F, **Pelicci PG**: Cardiac stem cells and diabetic cardiomyopathy. Chapter 16 - Part IV Cardiac progenitor cells and heart failure - Cardiovascular Regeneration and Stem Cell Therapy, Blackwell Futura Publishing, pp 161-9, 2007.
28. Viale A, **Pelicci PG**: Regulation of Self-Renewing Divisions in Normal and Leukaemia Stem Cells (Chapter 7). Cell Cycle Deregulation in Cancer, G.H. Enders Ed., Current Cancer Research, Part 3, 109-125, 2010.
29. Cambiaghi V, Giuliani V, Lombardi S, Marinelli C, Toffalorio F, **Pelicci PG**: Trim Proteins in Cancer (Chapter 6). TRIM/RBCC Proteins, Landes Biosciences, pp 77-91, 2012.
30. Vlachou, T, De Conti G, Sanarico, AG and Pelicci, PG. The leukemic Stem Cell. Acute Promyelocytic Leukemia, Springer, 2018, pp29-40.

31. Pelicci PG, Minucci S, Ravasio R. Cellule staminali tumorali. (Chapter 25). Patologia Generale, Idelson-Gnocchi, 2018, pp789-794
32. Ronchini C, Colombo E, Dellino I, Pelicci PG. Eterogeneita' genomica nei tumori (Chapter 17). In press